Insulin resistance, also known as impaired insulin sensitivity, is when someone has built a tolerance to insulin, the hormone responsible for regulating blood sugar levels.

Although insulin resistance precludes the development of type 2 diabetes, not everyone who has the condition will develop type 2 diabetes or its precursor, prediabetes. In fact, insulin resistance can be reversed with proper diet and exercise.

Here is what causes insulin resistance, how to recognize it, and the best treatment options.

Insulin resistance occurs when the cells in your muscles, fat, and liver are less responsive to insulin and therefore struggle to absorb glucose aka sugar in the blood.

Typically, you get a boost of sugar in your blood after you eat something containing carbohydrates. This boost signals to your pancreas to release insulin, which then helps your cells absorb the sugar and convert it to energy so you can function normally. Insulin resistance disrupts that process.

"When cells in the body become insulin resistant, more insulin is required to do the same job [aka lower blood sugar levels]," says Daniel Vatner, MD, an endocrinologist at Yale School of Medicine. "A person with insulin resistance needs to make much more insulin after a meal, or they will not be able to store and use sugar properly."

However, your body can only produce so much insulin on its own. So, there's a critical tipping point where your cells become so insulin resistant that they lose control over your blood sugar, and you end up with dangerous, chronically high blood sugar levels.

When there's too much sugar in your blood for too long, your body eventually stores it as fat. That's why insulin resistance increases the risk of being overweight and obesity-related conditions like:

Insulin resistance rarely comes with any noticeable symptoms. And most tests designed to detect insulin resistance are complicated and expensive.

Therefore, a healthcare provider will usually rely on tests that assess your blood sugar levels. These tests include:

All of these tests can also be used to diagnose prediabetes.

In rare cases, some people with insulin resistance may also develop a skin condition called acanthosis nigricans. This condition causes the skin to develop thick, dark, purplish patches, typically in the underarms, groin, or on the back of the neck.

Being overweight or obese can significantly increase your risk of insulin resistance, says Vatner.

"As an individual gains weight, fat can accumulate where it doesn't belong, as in the liver or the muscle," he says.

As fat gets into the cells, it can interfere with the cells' ability to respond to insulin, forcing the pancreas to make more insulin to compensate.

However, people of any size can also become insulin resistant.

You should regularly monitor blood sugar if you have risk factors for insulin resistance, such as obesity, a sedentary lifestyle, or a family history of type 2 diabetes . Even if you don't have these risk factors, you should start getting tested at the age of 45, says Mark Schutta, MD, medical director of the Penn Rodebaugh Diabetes Center.

Exercising and eating healthy are the most effective strategies for reversing insulin resistance. Even just a 5% to 10% loss in body weight can help to reverse insulin resistance, says Vatner.

Exercise not only plays an important role in weight management but can also help people with insulin resistance manage blood sugar. A 2016 review found that regular, moderately-intense physical activity like walking or biking for at least 30 minutes, three to five days a week was associated with improved insulin sensitivity as well as blood sugar control.

Schutta advises starting with a brisk 30- to 45-minute walk several days a week and then working your way up to 150 minutes of weekly moderate to vigorous aerobic exercise.

Important: Always consult with your physician before starting a new exercise program especially if you've been sedentary and/or have any pre-existing conditions to avoid injury.

Diet also plays a crucial role in managing and reversing insulin resistance. If you have insulin resistance, physicians may suggest you follow the Mediterranean diet, a plant-based diet, or a low-carb diet, like the Atkins diet.

In general, Schutta recommends limiting your intake of:

Schutta also recommends eating more:

Vatner says insulin-resistant patients with co-occurring conditions may be prescribed the following medications:

Insulin resistance is a serious, but treatable condition. If left untreated it could develop into prediabetes, metabolic syndrome, or type 2 diabetes, all of which increase your risk of heart disease and stroke.

While insulin resistance does not have any symptoms, it can be diagnosed through a blood sugar test.

To treat and reverse insulin resistance, eat a healthy diet full of fruits, vegetables, lean proteins, and whole grains while exercising for at least 150 minutes a week.

The rest is here:
How to reverse insulin resistance through diet and exercise - Insider

Recommendation and review posted by Bethany Smith

With the normal pressures of work compounded by the pandemic, stress and burnout are proliferating in the business world. Even before Covid-19, stress and burnout were ravaging the health of Americans. The number of hours worked is said by the non-profit American Institute of Stress to be the main source of job stress and this makes work especially problematic in the United States where Americans have a work ethic that is second to none.

A report a few years ago by the International Labor Organization showed that US workers averaged nearly 2,000 hours of work every year (40 hours per week x 52 weeks = 2,080 hours), or nearly 350 more hours per year (nine more weeks) than Europeans.

This is important because reducing stress is still the most important thing we can do for our health. Among other things, stress increases the risk of heart disease by 40 percent and the risk of stroke by 50 percent, and the American Institute of Stress tells us that three out of four doctors visits are for stress related ailments, and that stress is the basic cause of 60 percent of all disease and illness.

Whats the solution?

Many advocate shortening the work week. In Iceland, a trial from 2015 to 2019 of almost 3,000 people found that shortening the work week from 40 hours to 35 or 36 hours with no reduction in pay resulted in productivity either remaining the same or increasing over the working period, while perceived stress and burnout went down.

Microsoft Japan tried a four-day work week without a pay reduction over five weeks and reported happier workers and a 40% increase in productivity. And in 2018 Perpetual Guardian in New Zealand tried a four-day work week over 8 weeks for 240 of its staff. Employees there reported enjoying a better work-life balance and reported their stress levels decreased by 7%. The studies show that the workers reported less stress, but, of course, workers are motivated to praise shorter work weeks without pay reductions, and they may even be inspired to greater productivity during their working hours.

But there are doubters about this as a permanent solution, and, of course, some people find happiness in their work and dont want or need a shorter week. In all events, shortening the work week isnt a complete solution to stress and stress-induced disorders because of the myriad potential sources of stress that we encounter at work, at home, and in all our interactions. Is there then something we can add to better equip people to deal with the stresses and strains of life?

First, we should define stress to understand how we can best overcome it. Conversationally, we speak of the stress of the job or the stress of a divorce, ascribing the stress that people experience to an external event. However, more scientifically, stress refers to the internal bodily reactions to those events that are so disruptive to health.

The external events that are potentially stress-producing in the body are known as stressors or just stressful situations, to which individuals react very differently. One person in a given situation may suffer a stressful reaction such as a fight-or-flight response or a hormonal imbalance that can precipitate disease, whereas at least some people handle the situation with ease. Unfortunately, the latter appear to be in the minority.

A recent article in the Washington Post (What burnout really means, and what bosses and employees can do about it) tells us that the pandemic has caused prolonged stress to many, leading to burnout. Technically burnout is a combination of emotional exhaustion, and a reduced sense of personal accomplishment, and often a take this job and a shove it attitude. The author of the Post article says that experts say companies need to allow staff to set their own schedules, have meeting free days, proactively address rude workplace behavior, and avoid praising or normalizing working around the clock.

But these strategies, and even a shorter work week, seek to eliminate the stressors, but dont directly address the internal disorder that is stress, and they dont enhance our resilience to stressful stimuli. While eliminating stressors (if we can) may help in reducing future disruptions of the employees physical state, it does nothing to address the current internal disorder that leads to the headaches, stomach problems, high blood pressure, insomnia, and other stress-related disorders. And, of course, changing the work environment wont succeed for those companies unwilling or unable to change their environment. So, how do we overcome workplace stress?

Much stress is eliminated through night-time sleep. Although our bodies incur a heavy stress load on a regular basis, stress is a physical abnormality, which the body normalizes or heals whenever it is given the opportunity. When we become ill, we may relieve the symptoms with medicines, but Sir Hans Krebs, a Nobel Laureate in physiology, says The physician and the patient can do no more than assist nature, by providing the very best conditions for your body to defend and heal itself.

The rest we gain during sleep is a crucial requirement for assisting nature and allowing the body to heal itself. In fact, sleep is so important, it is part of every physicians prescription for virtually every disorder. However, while we naturally eliminate a lot of stress through sleep, the statistics tell us that most people are not winning their fight against stress and have come to accept being stressed as normal. We manage our stress with an increasing number of pharmaceuticals as we get older and think nothing of a full medicine cabinet to deal with our many disorders. If assisting nature is the key, what more can we do to help our bodies eliminate stress? How do we supplement our sleep if rest is so beneficial to health? This is where the yogis approach comes into play.

Research by co-author Dr. Wallace first published in Science and Scientific American in the 1970s showed that the meditation technique he analyzed, the Transcendental Meditation (TM) technique, produced a unique state of rest and orderliness in the mind and body, correcting physical disorders beyond what sleep had accomplished. His research showed that during the TM meditation session, the body gained a profound and unique state of rest. During the TM practice, even though the meditator was alert, the research showed remarkable decreases in oxygen consumption and respiration, reduced concentrations of blood lactate levels (high blood lactate is associated with anxiety), and a marked increase in skin resistance (associated with relaxation).

Later studies by Wallace and his colleagues showed reductions in cortisol (the stress hormone), as well as increases in serotonin (the happiness hormone), increases in blood flow to the brain, and perhaps most importantly, a marked coherence in the functioning of the brain. Sleep heals by creating order where there is disorder, but, interestingly, the rest during the Transcendental Meditation practice has been found to create more coherence, so in some respects it is more profound than what occurs during sleep.

The charts above show EEG brain wave measurements during sleep and the Transcendental Meditation technique. The mountains or spindles show periods when there is especially high coherence in the brain wave activity. High brain wave coherence is associated with memory, concept learning, creativity, high self-esteem, and reduced anxiety, depression, and other disorders, whereas abnormally low brain wave coherence is associated with autism, schizophrenia, Alzheimers, and other mental disorders. This is why researchers are so interested in studying brain waves.

And as can be seen from the charts, the individual who has been practicing TM for four months has significantly more brain wave coherence during the TM session than during sleep. And the five-year meditator has extremely high levels of brain wave coherence both during the meditation session and before and after meditating when just sitting with the eyes closed (see the EC or eyes closed period in the meditators charts). This is a level of coherence not found in other meditation practices.

Being resilient in the face of stress is also important since we cant possibly eliminate all the stressors in our lives. An article by Dr. Wallace recently published in Medicina describes a series of studies on TM that investigated the meditators response pattern to stressful stimuli as compared to a relaxation control group.

The meditators heart rates and other physiological measurements increased appropriately in response to stressful stimuli, but the meditators recovered much more quickly than the non-meditators, basically brushing off a situation that would tend to have a lasting effect on the non-meditators and disrupt their nervous systems. Dr. Wallace coined the phrase neuroadaptability to refer to the more resilient physiology that can better withstand stressful events.

Another interesting analysis by Dr. David Orme-Johnson, a former professor at Maharishi International University in Iowa (where all the students learn TM), determined that the number of medical visits of about 2,000 TM meditators were just a fraction of the number of visits of non-meditators of comparable age, gender, and profession, who had similar health insurance policies. Over the five-year study period, the TM meditators had significantly fewer incidents of illness in 17 medical treatment categories, including 87 percent less hospitalization for heart disease, 87 percent less for nervous system disorders, 73 percent less for nose, throat and lung diseases (including virus caused diseases), 65 percent less for metabolic disease, including diabetes, and 55 percent less for cancer.

Our new book, The Coherence Effect (Armin Lear Press, 2020), has many personal accounts of business people overcoming stressful work situations. Josh Griffith is one good example. He went from being burned out on the job to having the enthusiasm of a new hire. Josh has been the head writer for the popular daytime TV shows Days of Our Lives and The Young and the Restless. In 2013, he was having serious stress issues at work, and he started looking into meditation practices. Co-author Marcus interviewed Josh a few years ago after he had tried other techniques and had been practicing TM for a year. Josh said:

I saw a celebrated doctor on television and decided to try a meditation he said would help. So, I tried his meditation for about a year . . . . It was kind of helping, but then the work issues got worse and I was still feeling the same way that I had before.

Then Josh saw an interview about TM on television, and he decided to try it. He said:

In the world of daytime TV, youre having to create five shows a week. As head writer [The Young and the Restless] I was responsible for all the stories that aired. I walked away from it a few years ago because I felt burned out. It was too much of an output, and I didnt feel the quality of the output was something I could be proud of. It was taking such a toll on me that I walked away.

Then I started doing TM. I thought I was a meditator before starting TM. Boy, was I wrong. I was offered the head job on Days of Our Lives, and I agreed to take it because with TM I already felt sort of a creative energy bubbling back inside of me. So, I stepped back in, and it was sort of the case where I felt like Im back at the beginning of the career.

I felt like I had the energy that I had when I first started doing daytime. I was able to come in and the ideas flowed nonstop, whereas before I didnt know if I would be able to finish this. I was thinking I dont know what Im going to do Ive hit a wall. TM allowed me to generate so many story ideas that it was, in a way, sort of like a rebirth. You know Ive had a 30-year career. And the changes happened within a month of practicing TM. I feel like Im starting [my career] now. I feel like a 25-year-old again.

In years past, businesses have been slow to adopt meditation as a tool. That is changing and will change even more once businesses use brain-wave coherence as a means of evaluating different meditation programs. We have referred to some of the findings on Transcendental Meditation, a technique that we have each practiced for about 50 years. If you are interested in trying a meditation program, there are many to choose from, but we suggest letting science be the guide in selecting one, and we say the principal criterion needs to be the degree to which the program creates coherence in the mind and body, especially in the brain. Because the brain is the control center of the body, when the EEG activity is coherent, it has a maximum effect in creating the orderly and neurologically adaptive state that counteracts stress and makes us more resilient.

Written by Jay B. Marcus.

Read more from the original source:
A Yogi's Take on Stress and Burnout - CEOWORLD magazine

Recommendation and review posted by Bethany Smith

Females in Action South Coast is a Fall River-based organization for women that formed11 months ago during the COVID-19 pandemic.

Its member work out together at North Park in Fall River twice a week, Wednesdays at 6:15 p.m. and Saturdays at 8 a.m. There is no registration fee; just show up and get involved.

In addition to the workouts, members are also building friendships and helping their community along the way.

Organizer Caitlin Botelho and member Andrea Silvasaid this week on Townsquare Sunday that Females in Action is all about fitness, friendships, and philanthropy. The group has been involved in various charitable efforts during its first year.

Now the organization is looking to increase its numbers and expand to New Bedford.

Females in Action is actually a national programwith active groups in 20 states. It first began in North Carolina in 2013.

Caitlin Botelho, a Fall River native, was living in Tennessee at the time and became involved. She returned home in 2019 and started what's believed to be the first FiA chapter in the Northeast.

Both Caitlin and Andrea spoke about their experiences with FiA, and their hopes of getting more women involved. Their interview can be heard here:

Townsquare Sunday is a weekly public affairs program which airs Sunday at 6 a.m. and 11 am. on 1420 WBSM. The program highlights individuals and organizations working to make the SouthCoast a better place to live and work.

If you would like your organization featured on Townsquare Sunday, please e-mail the host at jim.phillips@townsquaremedia.com.

Read the original:
Fall River's Females in Action Hopes to Expand [TOWNSQUARE SUNDAY] - wbsm.com

Recommendation and review posted by Bethany Smith

TestoPrime is a dietary supplement that can help struggling with low testosterone levels. Testosterone is very important for overall male health as it can contribute to ones energy levels, stress response, muscle growth, sexual health and much more. It is common for men above the age of 40 to experience some sort of decline in their natural testosterone level. Issues such as erectile dysfunction, a lack of libido, weight gain, and low energy become common over time and even some younger people can suffer from the same problems. Taking a natural supplement that can boost the bodys natural testosterone levels can have a significant impact on ones overall health. TestoPrime is another addition to a long list of supplements that claim to boost natural testosterone levels in the body. Is the supplement worth purchasing? Does it work? Here is everything you need to know about TestoPrime.

Click Here to Visit the Official Website of TestoPrime

Who Is TestoPrime for?

TestoPrime is a natural supplement that anyone over the age of 18 can use. The supplement is intended for those men that are suffering from low testosterone levels as it can help bring them back to the level they need to be.

If youre experiencing some form of erectile dysfunction, low sex drive, low energy levels, fat gain, symptoms of depression, loss of body hair, chronic fatigue, and are extremely unmotivated, then you may be suffering from low testosterone levels. Testosterone is a very important hormone for male health, and it should not be overlooked.

(HUGE SAVINGS DEAL) Click Here To Buy TestoPrime at an Exclusive Low Price Today

TestoPrime is a natural supplement that can help improve the bodys ability to produce testosterone for great health benefits. The supplement is different from your average testosterone-booster as it consists of a natural formula that contains only pure and natural ingredients. TestoPrime also addresses the different reasons why your body may be suffering from low T-levels and promotes overall well-being without side-effects.

While many male enhancement supplements tend to have nasty side-effects, that is not the case with TestoPrime. The supplement consists of different antioxidants, minerals, and other nutrients that help improve the different mechanisms within the body for optimal health. Since the composition of the formula relies on natural ingredients, there are no side-effects making the supplement safe to consume. Although a prescription is not required to use TestoPrime, you should still consult your doctor if you are suffering from any other underlying health problem.

Overall, TestoPrime looks like the answer to the common problems faced by most men. If you are facing any of the problems mentioned above, then consider TestoPrime as its a safe and affordable option.

MUST SEE:We Found an Amazing Discounted Price For TestoPrime Pills Right Here

How Does It Work?

TestoPrime works by using a natural formula full of different powerful ingredients that support the bodys natural testosterone production mechanisms. However, thats not the only thing the supplement does, otherwise it would just be another testosterone booster. The ingredients inside the supplement also target the different things inside the body that could be contributing to low testosterone levels.

For example, stress is a big contributor to low T-levels and the supplement works inhibit the stress hormone cortisol to reduce the impact it has on the bodys testosterone levels. Similarly, there are different mechanisms inside the body that are responsible for converting testosterone into DHT (an androgen derived from testosterone), and estrogen. The ingredients inside the supplement work to reduce such mechanisms and prevent the conversion of testosterone. By reducing the rate at which testosterone is converted, and by promoting natural production of testosterone, TestoPrime can help support healthy T-levels in the body for fantastic health benefits.

Click Here to Get Testo Prime For The Lowest Discounted Price Online

Moreover, everything about TestoPrime is 100% safe and natural. As youll see listed below, the supplement uses a completely natural formula full of different ingredients that you may have already heard of. The manufacturers simply bring all the best ingredients under one supplement and use their purest and most potent forms for the best results. There are no side-effects of taking TestoPrime, and the manufacturing process also follows all the good manufacturing practices which helps keep the quality high.

Therefore, if youre in the market for a supplement that can help improve your health naturally, then TestoPrime might be the right choice for you. However, its recommended that one does their own research as well in order to make an informed decision.

ACT NOW AND SAVE! Get Testo Prime At an Amazing Discounted Price Online

TestoPrime Ingredients

>> Visit the Testo Prime official website today to place your order

(LIMITED SUPPLIES) Click Here to Buy TestoPrime at The Best Available Price Online

Benefits of TestoPrime

Some of the worth noting health benefits of TestoPrime are:

>> Also check what others are saying about this testosterone supplement. Does It Really Work? Click Here To Check Out TestoPrime Customer Reviews Now.

>> Try TestoPrime Now Visit the official website today to place your order.

Bonus Items

TestoPrime comes with two additional e-books free of cost if you opt for more than one bottle at checkout. These e-books are great resources for getting the most out of the supplement. The e-books are:

Pricing and Refund Policy

TestoPrime is a reasonably priced supplement that comes in three differently priced bundles priced as follows:

The price per bottle decreases as you go for the multi-bottle deals, and they become even better value for money thanks to the two free e-books that come with them. Each purchase of TestoPrime is also protected by the manufacturers 100% satisfaction guarantee. You can use the supplement for yourself and if you feel like it is not working out for you, then you can opt for a full refund; no questions asked.

Does TestoPrime Really Work?

TestoPrime has potential to be one of the best supplements out there. Men all over the world face many problems with their health due to low T-levels and the supplement can help counter that with its natural formula. TestoPrime can help improve muscle growth, reduce stress, promote fat loss, and much more thanks to a safe, and natural formula. The supplement also comes with two free guides that can help amplify its benefits. No side-effects, and the fact that the manufacturer is offering a money-back guarantee speaks volumes about the confidence they have in their product. Therefore, TestoPrime seems like a risk-free investment and worth a buy if youre looking to naturally boost your testosterone levels. You can purchase it from here.

SAFE PURCHASE Try TestoPrime on a Special Discounted Price Right Now

Disclaimer

Please note that any guidelines and advice given here are not a substitute for medical advice. Please consult your physician if you are under medication or have doubts following the advice/instructions given. Individual results may vary.

View post:
TestoPrime Reviews - Testo Prime Testosterone Booster - The Ritz Herald

Recommendation and review posted by Bethany Smith

DUBLIN, July 15, 2021 /PRNewswire/ -- The "Stem Cell Banking Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

The global stem cell banking market exhibited strong growth during 2015-2020. Stem cell banking is one of the most promising as well as the fastest growing segment of the next-generation stem cell therapy. It is the process of extracting, freezing and storing stem cells for potential future use. Some of the sources through which stem cells are obtained include embryo, umbilical cord, cord blood, placenta and bone marrow. These cells are used for treating a number of different diseases including diabetes, thalassemia, leukemia, sickle cell anemia and cardiac diseases. Moreover, they are also employed for generating platelets, red blood cells and white blood cells. The potential of stem cells to regenerate has led to their applications in tissue engineering, gene therapy and regenerative medicines. Looking forward, the publisher expects the global stem cell banking market to reach a value of US$ 21.5 Billion by 2026.

Global Stem Cell Banking Market Drivers:

Competitive Landscape:

The market is fragmented in nature with the presence various international as well as regional players.

Some of the leading players operating in the market are:

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

4.1 Overview

4.2 Properties

4.3 Key Industry Trends

5 Global Stem Cell Banking Market

5.1 Market Overview

5.2 Market Performance

5.3 Impact of COVID-19

5.4 Market Breakup by Product Type

5.5 Market Breakup by Service Type

5.6 Market Breakup by Bank Type

5.7 Market Breakup by Utilization

5.8 Market Breakup by Application

5.9 Market Breakup by Region

5.10 Market Forecast

6 Market Breakup by Product Type

6.1 Adult Stem Cells

6.1.1 Market Trends

6.1.2 Market Forecast

6.2 Human Embryonic Cells

6.2.1 Market Trends

6.2.2 Market Forecast

6.3 IPS Cells

6.3.1 Market Trends

6.3.2 Market Forecast

7 Market Breakup by Service Type

7.1 Sample Preservation and Storage

7.1.1 Market Trends

7.1.2 Market Forecast

7.2 Sample Analysis

7.2.1 Market Trends

7.2.2 Market Forecast

7.3 Sample Processing

7.3.1 Market Trends

7.3.2 Market Forecast

7.4 Sample Collection and Transportation

7.4.1 Market Trends

7.4.2 Market Forecast

8 Market Breakup by Bank Type

8.1 Private

8.1.1 Market Trends

8.1.2 Market Forecast

8.2 Public

8.2.1 Market Trends

8.2.2 Market Forecast

9 Market Breakup by Utilization

9.1 Used

9.1.1 Market Trends

9.1.2 Market Forecast

9.2 Unused

9.2.1 Market Trends

9.2.2 Market Forecast

10 Market Breakup by Application

10.1 Personalized Banking Applications

10.1.1 Market Trends

10.1.2 Market Forecast

10.2 Research Applications

10.2.1 Market Trends

10.2.2 Market Forecast

10.3 Clinical Applications

10.3.1 Market Trends

10.3.2 Market Forecast

11 Market Breakup by Region

11.1 North America

11.1.1 Market Trends

11.1.2 Market Forecast

11.2 Europe

11.2.1 Market Trends

11.2.2 Market Forecast

11.3 Asia Pacific

11.3.1 Market Trends

11.3.2 Market Forecast

11.4 Middle East and Africa

11.4.1 Market Trends

11.4.2 Market Forecast

11.5 Latin America

11.5.1 Market Trends

11.5.2 Market Forecast

12 Global Stem Cell Banking Industry: SWOT Analysis

12.1 Overview

12.2 Strengths

12.3 Weaknesses

12.4 Opportunities

12.5 Threats

13 Global Stem Cell Banking Industry: Value Chain Analysis

14 Global Stem Cell Banking Industry: Porters Five Forces Analysis

14.1 Overview

14.2 Bargaining Power of Buyers

14.3 Bargaining Power of Suppliers

14.4 Degree of Competition

Read more here:
Insights on the Stem Cell Banking Global Market to 2026 - by Product Type, Service Type, Bank Type, Utilization, Application and Region - WFMZ...

Recommendation and review posted by Bethany Smith

Scientists say that base editing proved itself efficient in correcting a mutation in patient cells with the monogenic disease Alpha-1 antitrypsin deficiency (AATD). The disorder is a common inherited disease that affects the liver and the lungs.

Base editing is different from other forms of editing, including CRISPR, because the base editors do not induce a break in the DNA, which helps prevent double strand breaks, potential off-target editing, and unwanted mutations during cell repair.

Researchers at Boston Medical Center and Boston University used patient-derived liver cells (iHeps) that mimic the biology of liver hepatocytes, the main producers of alpha-1 antitrypsin protein in the body. The base editing technology corrected the Z mutation responsible for AATD and reduced the effects of the disease in the hepatocytes, demonstrating successful base editing in human cells.

The study (Adenine Base Editing Reduces Misfolded Protein Accumulation and Toxicity in Alpha-1 Antitrypsin Deficient Patient iPSC-Hepatocytes), published inMolecular Therapy,can help pave the way for future human trials, according to the research team.

AATD is most commonly caused by the Z mutation, a single base substitution that leads to AAT protein misfolding and associated liver and lung disease. In this study, we apply adenine base editors to correct the Z mutation in patient-induced pluripotent stem cells (iPSCs) and iPSC-derived hepatocytes (iHeps), wrote the investigators.

We demonstrate that correction of the Z mutation in patient iPSCs reduces aberrant AAT accumulation and increases its secretion. Adenine base editing (ABE) of differentiated iHeps decreases ER stress in edited cells as demonstrated by single-cell RNA sequencing. We find ABE to be highly efficient in iPSCs and do not identify off-target genomic mutations by whole genome sequencing.

These results reveal the feasibility and utility of base-editing to correct the Z mutation in AATD patient cells.

This study shows the successful application of base editing technology to correct the mutation responsible for AATD in liver cells derived from patients with this disease, said Andrew Wilson, MD, a pulmonologist at Boston Medical Center and an associate professor of medicine at the Boston University School of Medicine, who served as the studys corresponding author. I am hopeful that these results will create a pathway to use this technology to help patients with AATD and other monogenic diseases.

Base editors created by Beam Therapeutics were applied to induced pluripotent stem cells (iPS cells) from patients with AATD, and then again in hepatocytes that were derived from iPS cells. This was done to study the correction of the Z mutation of the gene responsible for AATD in human cells.

The Z mutation in the SERPINA1 gene is responsible for causing chronic, progressive lung and liver disease in AATD. In patients with AATD, the mutant AAT proteins misfold and form aggregates of protein that build up inside the hepatocytes and cause damage.

For this study, researchers started with mutant (ZZ) iPSCs created from a patient with AATD. After the base editing process was completed, the DNA from the edited cells was sequenced to determine if the SERPINA1 gene had been corrected. Clonal populations of cells with either one (MZ) or both copies (MM) of the corrected gene were expanded and then differentiated over the course of 25 days to generate hepatocytes.

After sequencing the entire genome of the edited cells, there was no evidence of inadvertent mutations in the genome from the base editors, and the misfolding and associated protein buildup was partially corrected in MZ cells and completely in MM normal cells.

The process was repeated using hepatocytes derived from the mutant iPSCs. Two base editors were used in different conditions to test the efficiency of this process. In the best conditions, about 50% of the mutant genes were successfully edited. The cells were then analyzed to see if they still appeared hepatic and if there were fewer signs of the disease in the edited cells, compared to mutant ZZ cells.

Findings showed the base editing did not alter the hepatic program, and the liver cells still expressed hepatic genes and proteins at normal levels. In addition, there was less accumulation of aggregated misfolded Z AAT protein, showing less evidence of disease in the edited cells.

While augmentation therapy has been shown to slow the progression of lung disease in AATD patients, there are currently no treatments available for AATD-associated liver disease. Emerging treatment strategies have focused on the correction of the Z mutation.

Base editing is being evaluated as a treatment modality for a variety of monogenic diseases, according to the scientists. Alpha-1 antitrypsin deficiency is a prime target for base editing, likely to be one of the earlier diseases in which base editors are tried in human studies. Additional disease targets include retinal disease, hereditary tyrosinemia, sickle cell anemia, progeria, cystic fibrosis, and others.

Findings of this study suggest that future research may explore the usefulness of base-editors in editing other quiescent cell populations. Additionally, it has recently been shown that base-editors can edit RNA in addition to DNA in immortalized cell lines and warrants further investigation.

By quiescent, we are referring to differentiated cells (in this case hepatocytes) that are not stem cells or cells that are actively dividing. Basically, [we are talking about] any differentiated cell type, Wilson toldGEN. This is relevant because many of the cell types in the body that you would want to target are already differentiated cells. It is in many cases easier to edit an actively dividing cell, which is why we mention this. There are many examples of a differentiated cell type in the body, such as cardiac cells, lung cells, skin cells, etc., that you might want to target.

One of the major things researchers worry about in the field of gene editing is the possibility of off-target effectsunintended consequences of applying the editing machinery.

The most likely off-target effect, in this case, would be editing of DNA somewhere in the genome other than what we intended to edit, continued Wilson. When we looked by whole genome sequencing, we didnt see evidence of this in iPS cells. However, in addition to editing DNA, it has been reported that base editors can also edit RNA. This could have unintended consequences even if the DNA sequence isnt changed.

We didnt look in this study to see if this occurred, which is why we mentioned itjust to be up front about possible unintended consequences/toxicities that could be present and that we didnt exclude. It isnt something specific to our study or gene of interest but generalizable to the entire field of base editing.

Read more:
Base Editing as Therapy for Common Inherited Lung and Liver Disease Shows Promise - Clinical OMICs News

Recommendation and review posted by Bethany Smith

SAN DIEGO--(BUSINESS WIRE)--Stemson Therapeutics announced today the closing of a DCVC Bio-led $15 million Series A financing to advance development of Stemsons proprietary therapeutic solution to cure hair loss. Genoa Ventures, AbbVie Ventures and other investors join in supporting Stemsons efforts to restore human hair growth with a novel cell regeneration technology using the patients own cells to generate new hair follicles.

In addition, Kiersten Stead, Ph.D., Co-Managing Partner at DCVC Bio and Jenny Rooke, Ph.D., Managing Director at Genoa Ventures will join Stemsons Executive Chairman Matt Posard and Chief Executive Officer and co-founder Geoff Hamilton on the board of directors. Dr. Stead invests in early-stage companies that build novel deep tech businesses in the life sciences. Stead received a Ph.D. in Molecular Biology & Genetics and an MBA in finance from the University of Alberta. Dr. Rooke is founder and Managing Director at Genoa Ventures where she specializes in early-stage companies innovating at the convergence of technology and biology. Rooke received a Ph.D. in Genetics from Yale University and a degree in physics from the Georgia Institute of Technology.

We are excited and honored to welcome DCVC Bio and a fantastic syndicate of investors to the Stemson team. The Series A funding will help us optimize our solution for human skin structure and environment so we can go into our first human clinical trial with high confidence for a positive outcome. We have the technical and biological building blocks to successfully address hair loss that overcomes failures of past therapies, said Hamilton. The addition of key venture capital investors DCVC Bio, Genoa Ventures and AbbVie Ventures broadens and strengthens our investor base. DCVC Bio and Genoa Ventures are successful early-stage development investors, and I am pleased to welcome Dr. Stead and Dr. Rooke, our newest board members, to the team. In addition, the AbbVie Venture investment comes on the heels of an initial seed investment from Allergan Aesthetics in 2020, and the continued industry interest in our technology is encouraging.

Globally, hundreds of millions of men and women suffer from various forms of hair loss. Though there are many possible causes of hair loss, including chemotherapy, autoimmune disease, scarring, and genetics, all can result in a loss of self-esteem and cause depression, anxiety and other mental health disruption for those affected. The hair restoration market is expected to exceed $13.6 billion by 2028, and no solution today is capable of generating an unlimited new supply of healthy follicles for patients in need.

Almost 30 years have passed since the last FDA-approved hair loss treatment, yet millions still suffer the physical and mental impact of losing their hair each year, stated Dr. Stead. Stemsons novel stem cell engineering platform has the potential to cure hair loss once and for all, treating not only the physical symptoms of this complex problem, but the mental burden as well.

"The team at Genoa is impressed with Stemsons vision to blend biology and technology and apply it beyond traditional biotech," added Dr. Rooke. "By combining exciting advancements in iPSCs with novel technologies in materials and data sciences, Stemson exemplifies the kind of chimeric teams Genoa seeks to support on their journey to become a category-defining company."

The Series A financing brings the total funding raised to date to $22.5 million and allows Stemson to further the next stage of research and development of its cell engineering platform, where is it being combined with bioengineered material and robotic delivery as a novel solution for natural hair replacement. Currently, Stemsons research and development efforts are focused on developing an optimized solution for human skin structure environment in larger animal models. Stemsons Induced Pluripotent Stem Cell (iPSC) based technology is capable of producing the cell types required to initiate hair follicle growth and have been successfully tested in small animal models.

About Cell Regeneration Technology

Human Induced Pluripotent Stem Cells (iPSC) have the unique capability to replicate indefinitely and give rise to all cell types of the human body, including the cell types required for repair. iPSC-based technology is capable of producing the cell types required to initiate hair follicle growth. As a new therapeutic platform, iPSCs represent an emerging area of regenerative cell therapy. Stemson is one of a growing number of companies at the forefront in developing iPSC-based treatments.

About DCVC Bio

For over twenty years, DCVC and its principals have backed brilliant entrepreneurs applying Deep Tech, from the earliest stage and beyond, to pragmatically and cost-effectively tackle previously unsolvable problems in nearly every industry. DCVC Bio specializes in supporting life sciences platform companies at the intersections of engineering and therapeutics, industrial biotechnology and agriculture. For more information, please visit https://www.dcvc.com/companies.html#dcvc-bio

About Genoa Ventures

Genoa Ventures invests in early-stage companies working at the convergence of biology & technology to accelerate the pace of innovation, transform industries, and solve some of the most fundamental challenges to life. Genoa, identifies opportunities early and focuses its investments and expertise to empower the next great category-defining companies. The Genoa team has a unique chimeric blend of experience from scientific research and discovery to executive management in the life sciences and technologies sectors. The team applies this diverse experience to provide expert guidance to its companies and stellar returns to its investors.

About AbbVie Ventures

AbbVie Ventures is the corporate venture capital group of AbbVie. We are a strategic investor, investing exclusively in novel, potentially transformational science aligned with AbbVie's core R&D interests. We measure success primarily by the extent to which our investments foster innovation with potential to transform the lives of patients that AbbVie serves. AbbVie Ventures enables its portfolio companies with both funding as well as access to AbbVie's internal network of experts across all phases of drug development, from drug discovery through commercialization. For more information, please visit http://www.abbvie.com/ventures

About Stemson Therapeutics

Stemson Therapeutics is a pre-clinical stage cell therapy company founded in 2018 with a mission to cure hair loss by leveraging the regenerative power of Induced Pluripotent Stem Cells. Based on the breakthrough innovation by Stemson Therapeutics co-founder, Dr. Alexey Terskikh, Stemson uses iPSC to regenerate the critical cells required to grow hair and which are damaged or depleted in patients suffering from hair loss. The iPSC-derived cells are used to grow de novo hair follicles, offering a new supply of hair to treat people suffering from various forms of Alopecia. Today, there are no available treatments capable of growing new hair follicles. Stemsons world class team of scientists, advisors and collaborators are passionate about delivering a scientifically based, clinically tested cure for hair loss to the millions of hair loss sufferers who seek help for their hair loss condition. Stemson Therapeutics is headquartered in San Diego, CA. For more information, please visit http://www.stemson.com.

Read the original:
Stemson Therapeutics Secures $15M Series A Funding to Cure Hair Loss - Business Wire

Recommendation and review posted by Bethany Smith

Some people involved in a class action against two fertility services over the use of a non-invasive test which may have incorrectly classifiedembryos as abnormalhave been told their embryos are still being stored.

The lawyer representing about 200 affected parties in Victoria's Supreme Court saidthe mistake hadresulted in some women choosing to beimplanted with another person's embryo, while others have lost precious months of fertility.

The class action launched lastDecember alleges Melbourne-based Monash IVF and Adelaide-based Repromed breachedtheir duty of care by failing to tell patients about the pitfalls of a type of testing that does not require a biopsy.

There are two ways to conduct such testing: the first method is through a biopsy, which involves taking a tissue sample from an embryo, a method that is considered invasive.

The second method is called non-invasive pre-implantation genetic testing and involves collecting DNA from the culture that the embryo has been growing in while in the laboratory.

The inaccuracy of the test used by the two services between May 2019 and October 2020 was discovered last October.

Patients were informed of the issue after manyhad already made the choice to donatethe embryos to science or destroy them.

Lawyer Michel Margalit said some clients had discovered last week that some oftheir embryos were still in storage.

Supplied

Those that had been donated could still be retrieved, but the others were lost forever.

"They acted on the advice that their embryos were abnormal or had been destroyed," Ms Margalit said.

"Some people obtained donor embryos and are now pregnant with children that aren't necessarily genetically related to them, or that had a whole host of other treatments, so it's a very painful time for our clients."

She said they were not told about the pitfalls of the experimental testing regime.

"In this case, there was an alternative a reliable test, a biopsy method and women were steered away from that method, to this non-invasive method and they just didn't know the mess they were walking into," she said.

Monash IVF and Repromed have now stopped using non-invasive pre-implantation genetic testing.

Repromed medical directorProfessor Kelton Tremellen said the test turned out to be not as accurate as the company had hoped.

He said some of the embryos that could now be used might still be abnormal.

Supplied: Repromed

"What we're trying to do is say, look, unfortunately, we've now recognised that the test is not as accurate as it was originally portrayed to us and that we want to give these individuals the opportunity to make a decision nowwhat they want to do with those embryos," he told ABC Radio Adelaide.

"Some people will say 'I simply don't want to use them, we've moved on'.

"Others will say, 'look, we'll accept the risk and transfer them and effectively consider them to be embryos that haven't been tested at all'."

He said he and other scientists had "lost sleep" worrying about the effect on patients.

"Rather than hide this stuff from patients, our staff have contacted them saying, 'look, those embryos are still in storage, we've now found out this test is not as accurate as we'd hoped, what would you like to do with them?'" he said.

"Rather than sweeping it under the carpet, we're trying to be open and socially responsible by having full disclosure."

Continue reading here:
IVF patients suing over inaccurate genetic tests find out some of their embryos were not discarded - ABC News

Recommendation and review posted by Bethany Smith

Small-cell lung cancer (SCLC) occurs almost exclusively in smokers and appears to be most common in heavy smokers. Historically, SCLC has been rare in never smokers. However, certain inherited mutations may increase the likelihood of developing SCLC.

It is very important to note that having inherited a genetic mutation does not mean a person will develop SCLC.

Although there are several different kinds of lung cancer, around 95% of lung cancers are either SCLCs or non-small cell lung cancers (NSCLCs).

What distinguishes SCLC from NSCLC is its rapid growth and the early development of widespread metastases. Although SCLC is initially very responsive to chemotherapy and radiation, the majority of patients will relapse within a few months to 1 year from initial therapy.

This article will look at whether SCLC is hereditary and whether a person can undergo genetic testing. It will also discuss the causes of and risk factors for SCLC.

SCLC occurs when certain cells in the lungs grow quickly and uncontrollably, forming a tumor.

Cancers begin to develop when genetic mutations affect the genes that control the growth and division of cells or repair DNA that is damaged.

The majority of lung cancer cases are due to genetic changes known as somatic mutations, which are not hereditary. A person acquires them during their lifetime.

The National Organization for Rare Disorders notes that the two main somatic mutations related to SCLC affect the genes TP53 and RB1.

The TP53 gene provides instructions for creating a protein called p53, and the RB1 gene provides instructions for making pRB. Both proteins are tumor suppressors, which means they regulate cell growth and division.

However, in 2021, a group of researchers published a scientific paper that looked at 87 people with SCLC.

After analyzing 607 genes from each individual, the researchers found genetic mutations that increased the likelihood of developing SCLC in 43.7% of the study participants. Around 10% of these are heritable genetic mutations.

The authors of the paper conclude that certain heritable genetic mutations could make some people more likely to develop SCLC.

It is of note that if a person inherits a genetic mutation, this can increase their risk of developing cancer. It does not mean, however, that they will definitely develop cancer.

In addition, the American Cancer Society states that, although genes can play a role in the development of lung cancer, few lung cancers occur due to inherited mutations alone.

Genetic testing is when healthcare professionals look for potential inherited genetic mutations that may increase a persons risk of developing certain kinds of cancer.

For some cancer types, a healthcare professional can also suggest genetic testing as a part of the diagnostic and staging process. This can help determine a persons outlook and whether particular treatment options might be helpful.

Currently, however, doctors do not use genetic testing to diagnose SCLC. The Memorial Sloan Kettering Cancer Center notes that healthcare professionals and researchers know less about the genetic mutations that can lead to SCLC than they do about other genetic changes.

Smoking is the primary cause of SCLC. Tobacco smoke contains cancer-causing chemicals, or carcinogens, which damage the DNA in cells.

According to a 2020 review, 85% of lung cancer cases are the result of smoking.

Other risk factors include exposure to:

There are several ways in which a person may be able to lower their risk of developing SCLC.

Smoking tobacco is such a common cause of SCLC that the most effective preventive strategy is to not begin smoking.

However, for those who do smoke, quitting can lower the likelihood of developing SCLC. If a person quits before cancer develops, the lung tissue can begin to gradually repair itself.

A 2018 study looked at a group of people who have smoked 21.3 packs of cigarettes per year on average. The researchers compared the lung cancer rates of those who currently smoke and those who had quit within the previous 5 years.

They found that the individuals in the latter group were 39.1% less likely to develop lung cancer.

Learn about 11 tips for giving up smoking here.

Other ways of lowering the risk of SCLC include reducing exposure to secondhand smoke, asbestos, and radon. However, this may sometimes be outside of a persons control.

At the moment, doctors do not use genetic testing to diagnose SCLC.

Instead, a person should contact a healthcare professional if they experience any of the following symptoms:

If a healthcare professional suspects the cause of the above symptoms is SCLC, they may perform the following diagnostic tests:

Cancer occurs due to genetic mutations that lead to an uncontrollable growth and division of cells.

A person can acquire these genetic mutations throughout their life. In some cases, certain hereditary genes can increase the risk of developing SCLC.

However, inherited genetic mutations are often not enough to cause cancer by themselves. Having inherited a genetic mutation does not mean a person will develop cancer. It means that it can increase the likelihood of that happening.

Smoking is the primary cause of SCLC. To help lower the risk of developing this type of cancer, a person should avoid smoking.

Read the original:
Is small-cell lung cancer hereditary? What to know - Medical News Today

Recommendation and review posted by Bethany Smith

NEW YORK Foundation Medicine and Flatiron Health announced this week that Foundations comprehensive genomic profiling tests will be available to order through Flatiron's OncoEMR platform. The integration will allow clinicians to electronically order, track, and receive Foundations test through OncoEMR, the companies said. Both Flatiron and Foundation are planning further integrations with the others comprehensive genomic profiling tests and electronic medical record systems, respectively.

Myriad Genetics this week said it has completed the sale of its Myriad RBM unit which specializes in providing laboratory research services to pharmaceutical companies to IQVIA subsidiary Q2 Solutions. When Myriad announced its intent to sell this business unit in May, it did not disclose the deal's financial details.

GenetronHealth said this week that it has entered a new partnership with the World Economic Forum under its Health and Healthcare Platform, where it is contributing its research insights, technologies, and industry experience. The platform's overall goal is to ensure worldwide equal access to the highest standards of health and healthcare.Genetroniscurrentlyparticipating in a sub-project,dubbedMoving Genomics to the Clinic, which seeks to promote the use of genetic testing in routine clinical practices by proving its utility and efficacy.

AccessHope, a City of Hope subsidiary, said this week that it has partnered with the Dana-Farber Cancer Institute to bring the latest cancer care expertise to patients and oncologists in the community. By partnering withAccessHope, Dana-Farber's experts will support oncologistswiththe latest advances in oncology,includingpersonalized treatments, clinical trials, promising investigational medications, and molecular testing. Patients in Massachusetts, Maine, New Hampshire, Vermont, Connecticut, Rhode Island, New York,and New Jersey, as well asthosein other parts of the country,can access these services through their employee benefits programs. City of Hope and Northwestern University's Robert H. Lurie Comprehensive Cancer Center are also foundational members ofAccessHope.

Molecular breath analysis startup Deep Breath Intelligencesaid this week that it has entered a collaboration with Lwenstein Medical, a sleep and respiratory medicine firm based inRheinland-Pfalz, Germany.Rotkreuz, Switzerland-based DBI said that it is applying artificial intelligence to identify breath biomarkers related to obstructive sleep apnea syndrome. DBIsaid ithas initiated a study on OSASin collaboration with Lwenstein Medical,using participantsbreath samples and applying DBIs patterned analytical algorithms to provide results.

Enable Biosciences said this week it is partnering with the California Department of Public Health to survey state residents for the presence of antibodies against SARS-CoV-2. As part of the program, more than 200,000 households in California will be invited to submit dried blood samples collected at home using kits developed by Enable Bio andtheCDPH. The samples will then be tested by Enable Bio for the presence of antibodies against SARS-CoV-2 to distinguish antibody response fromviralinfection versusresponse fromvaccination. Test results will provide information about the spread of COVID-19 in California and the uptake of vaccines for the disease, South San Francisco, California-based Enable Bio said. The project is a collaboration betweenthe company,theCDPH, Stanford University, and Gauss Surgical. The first survey period concluded June 15 with the second and third enrollment periods slated tobeginat the start of 2022.

NeoGensaid this week that it has extended itsglobalanimal genomicspartnership withGencove. Thepartnership allowsNeoGento offerGencove'sSkimSeeklow-pass sequencing technology to customers in the agricultural sector, including those in the bovine, canine,poultry, and swine industries. UsingGencove'ssequencingimputationplatform,NeoGensaid it can deliver increased genomics data with improved accuracy and flexibility.

Bioceptsaid this week ithas been added to the Russell Microcap Index. Michael Nall, Biocept's president and CEO,called the nodexceptionally exciting, as a driver ofawarenessfor the cancer liquid biopsy firm within thelargerglobal investment community.

Immunoviasaid this week that its American subsidiary hasreceived a CLIA Certificate of Registration,which isan important step in the accreditation of its laboratory in Marlborough, Massachusetts, and a prerequisite to receiving clinical laboratory licensure fromtheMassachusetts Department of Public Health. Clinical laboratory licensure is required beforeImmunoviacan begin testing patients with itsImmrayPanCan-d test, the firm said.According to the Centers for Medicare and Medicaid Services, a Certificate of Registration allows a laboratory toconduct moderate and/or high complexity testing until it is inspected to determine its compliance with the CLIA regulations.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared onGenomeWeb.

Continued here:
In Brief This Week: Foundation Medicine, Myriad Genetics, Genetron Health, and More - GenomeWeb

Recommendation and review posted by Bethany Smith

Dublin, July 05, 2021 (GLOBE NEWSWIRE) -- The "Genomic Cancer Panel and Profiling Markets by Cancer, by Application, by Tissue and by Gene Type with Screening potential Market Size, Forecasting/Analysis, and Executive and Consultant Guides 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Cancer Gene Panels and Genomic Profiling are quickly changing the diagnosis and treatment of cancers. The market is moving out of a specialized niche and going mainstream as Oncologists begin routinely using information on the hundreds of genes related to cancer. The market is exploding as physicians use all the information they can get in the battle against cancer. While Pharmaceutical Companies see the potential to make nearly any therapy viable. The report has data on how test volumes have grown for the biggest players. Find out how this new way of understanding cancer will change cancer diagnostics forever.

Comprehensive panels, genomic profiling, high risk breast cancer panels. Learn all about how players are jockeying for position in a market that is being created from scratch. And some players are pulling way out in front and expanding globally. It is a dynamic market situation with enormous opportunity where the right diagnostic with the right support can command premium pricing. And the science is developing at the same time creating new opportunities with regularity. And the cost of sequencing continues to fall.

This report provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2021 United States Medicare Fee Payment Schedules to help understand test pricing in detail. Forecast demand for new testing regimes or technologies. Make research investment decisions. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth.

Key Topics Covered:

1 Market Guides

2 Introduction and Market Definition

3 Market Overview3.1 Players in a Dynamic Market3.1.1 Academic Research Lab3.1.2 Diagnostic Test Developer3.1.3 Instrumentation Supplier3.1.4 Distributor and Reagent Supplier3.1.5 Independent Testing Lab3.1.6 Public National/regional lab3.1.7 Hospital lab3.1.8 Physician Office Labs3.1.9 Audit Body3.1.10 Certification Body3.2 Oncogenomics3.2.1 Carcinogenesis3.2.2 Chromosomes, Genes and Epigenetics3.2.2.1 Chromosomes3.2.2.2 Genes3.2.2.3 Epigenetics3.2.3 Cancer Genes3.2.4 Germline vs Somatic3.2.5 Gene Panels, Single Gene Assays and Multiplexing3.2.6 Genomic Profiling3.2.7 The Comprehensive Assay3.2.8 Changing Clinical Role3.2.9 The Cancer Screening Market Opportunity3.3 Cancer Management vs. Diagnosis3.3.1 The Role of Risk Assessment3.3.2 Diagnosis3.3.3 Managing3.3.4 Monitoring3.4 Phases of Adoption - Looking into The Future3.5 Structure of Industry Plays a Part3.5.1 Hospital Testing Share3.5.2 Economies of Scale3.5.2.1 Hospital vs. Central Lab3.5.3 Physician Office Lab's3.5.4 Physician's and POCT3.6 Currently Available Large Comprehensive Assays3.7 Pricing Profiling vs. Whole Exome (or Genome) Sequencing3.7.1 Medicare Profile Pricing3.7.2 Whole Exome Sequencing

4 Market Trends4.1 Factors Driving Growth4.1.1 Level of Care4.1.2 Companion Dx4.1.3 Immuno-oncology4.1.4 Liability4.1.5 Aging Population4.2 Factors Limiting Growth4.2.1 State of knowledge4.2.2 Genetic Blizzard4.2.3 Protocol Resistance4.2.4 Regulation and coverage4.3 Instrumentation and Automation4.3.1 Instruments Key to Market Share4.3.2 Bioinformatics Plays a Role4.4 Diagnostic Technology Development4.4.1 Next Generation Sequencing Fuels a Revolution4.4.2 Single Cell Genomics Changes the Picture4.4.3 Pharmacogenomics Blurs Diagnosis and Treatment4.4.4 CGES Testing, A Brave New World4.4.5 Biochips/Giant magneto resistance based assay

5 Cancer Panels & Profiles Recent Developments5.1 Recent Developments - Importance and How to Use This Section5.1.1 Importance of These Developments5.1.2 How to Use This Section5.2 Dante Labs Acquires Cambridge Cancer Genomics5.3 Celemics, Strand Partner on Integrated Platform for NGS Analysis5.4 Myriad Genetics Recalibrates Breast Cancer Panel for All Ancestries5.5 Burning Rock Revenues Rise5.6 Caris Life Sciences to Expand Liquid Biopsy Testing5.7 OncoDiag Announces Multiplex Test for Bladder Cancer Recurrence5.8 Intermountain and Myriad Combine Test Offering5.9 Illumina, Geneseeq to Offer Cancer Testing Kits in China5.10 Exact Sciences to Offer End-to-End Cancer Testing5.11 Guardant Health Turns to Tumor Tissue Sequencing5.12 Tempus Inks Oncology Testing Collaboration With Bayer5.13 Biocartis Collaborating With GeneproDx, Endpoint Health on Tests for Idylla Platform5.14 Wales to Routinely Screen Cancer Patients With Yourgene Elucigene Test5.15 Metastatic Cancer Markers Identified in Clinical WGS Study5.16 Stitch Bio Bets on CRISPR Tech5.17 Bayer, LifeLabs Launch Free NTRK Genetic Testing Program5.18 Foundation Medicine Liquid Biopsy Gets FDA Approval for Multiple Companion Dx5.19 Progress, Challenges in Liquid Biopsy Reimbursement5.20 Israeli Startup Curesponse Raises $6M5.21 Invitae, ArcherDX Merge to Advance Precision Oncology Offerings5.22 MD Anderson Precision Oncology Decision Support to Use Philips' Informatics Solution5.23 NeoGenomics, Lilly Oncology Partner for Thyroid Cancer Testing Program5.24 Germline Results Guides Precision Therapy in Advanced Cancer5.25 FDA Clears Cancer Genomic Profiling Kit From Personal Genome Diagnostics5.26 ArcherDX, Premier Collaborate to Evaluate Genomic Sequencing Assay for Cancers5.27 Labs Reporting Cancer Risk Mutations from Tumor Testing5.28 Users Begin Integrating Genomics Data for Clinical Decision Support5.29 Fujitsu Improves Efficiency in Cancer Genomic Medicine5.30 Thermo Fisher's automated sequencer to offer same-day, pan-cancer test results5.31 Universal Genetic Testing for All Breast Cancer Patients5.32 Exact Sciences buys Genomic Health5.33 Multi-Gene Liquid Biopsy Breast Cancer Panel5.34 Thrive to Develop Earlier Detection of Multiple Cancer Types5.35 New Gene Panel Identifies High Risk Prostate Cancer5.36 Guardant Health Liquid Biopsy Test to be Covered by EviCore5.37 Biocept Partnership Offering for Liquid Biopsy Adds Several Key Services5.38 Natera Commercializes Tumor Whole Exome Sequencing from Plasma5.39 Inivata Completes 39.8M Series B Funding Round5.40 Bio-Rad Clinical ddPCR Test, Diagnostic System Get FDA Clearance5.41 CellMax, Medigen Biotech Partner in Colorectal Cancer Clinical Trials5.42 Biodesix Acquires Integrated Diagnostics5.43 Predicine, Kintor Pharmaceuticals Partner on Clinical Trials, CDx

6 Profiles of Key Players6.1 10x Genomics, Inc6.2 Abbott Diagnostics6.3 AccuraGen Inc6.4 Adaptive Biotechnologies6.5 Aethlon Medical6.6 Agena Bioscience, Inc6.7 Agilent/Dako6.8 Anchor Dx6.9 ANGLE plc6.10 ApoCell, Inc.6.11 ArcherDx, Inc6.12 ARUP Laboratories6.13 Asuragen6.14 AVIVA Biosciences6.15 Baylor Miraca Genetics Laboratories6.16 Beckman Coulter Diagnostics6.17 Becton, Dickinson and Company6.18 BGI Genomics Co. Ltd6.19 Bioarray Genetics6.20 Biocartis6.21 Biocept, Inc6.22 Biodesix Inc6.23 BioFluidica6.24 BioGenex6.25 BioIVT6.26 Biolidics Ltd6.27 bioMerieux Diagnostics6.28 Bioneer Corporation6.29 Bio-Rad Laboratories, Inc6.30 Bio-Reference Laboratories6.31 Bio-Techne6.32 Bioview6.33 Bolidics6.34 Boreal Genomics6.35 Bristol-Myers Squibb6.36 Burning Rock6.37 Cancer Genetics6.38 Caris Molecular Diagnostics6.39 Castle Biosciences, Inc.6.40 Celemics6.41 CellMax Life6.42 Cepheid (Danaher)6.43 Charles River Laboratories6.44 Chronix Biomedical6.45 Circulogene6.46 Clinical Genomics6.47 Cynvenio6.48 Cytolumina Technologies Corp6.49 CytoTrack6.50 Datar Cancer Genetics Limited6.51 Diagnologix LLC6.52 Diasorin S.p.A6.53 Enzo Life Sciences, Inc6.54 Epic Sciences6.55 Epigenomics AG6.56 Eurofins Scientific6.57 Exact Sciences6.58 Exosome Diagnostics6.59 Exosome Sciences6.60 Fabric Genomics6.61 Fluidigm Corp6.62 Fluxion Biosciences6.63 Foundation Medicine6.64 Freenome6.65 FUJIFILM Wako Diagnostics6.66 GeneFirst Ltd.6.67 Genetron Holdings6.68 GenomOncology6.69 GILUPI Nanomedizin6.70 Grail, Inc.6.71 Guardant Health6.72 HalioDx6.73 HansaBiomed6.74 HeiScreen6.75 Helomics6.76 Horizon Discovery6.77 HTG Molecular Diagnostics6.78 iCellate6.79 Illumina6.80 Incell Dx6.81 Inivata6.82 Integrated Diagnostics6.83 Invitae Corporation6.84 Invivogen6.85 Invivoscribe6.86 Janssen Diagnostics6.87 MDNA Life SCIENCES, Inc6.88 MDx Health6.89 Menarini Silicon Biosystems6.90 Millipore Sigma6.91 Miltenyi Biotec6.92 MIODx6.93 miR Scientific6.94 Molecular MD6.95 MyCartis6.96 Myriad Genetics/Myriad RBM6.97 NantHealth, Inc.6.98 Natera6.99 NeoGenomics6.100 New Oncology6.101 NGeneBio6.102 Novogene Bioinformatics Technology Co., Ltd.6.103 Oncocyte6.104 OncoDNA6.105 Ortho Clinical Diagnostics6.106 Oxford Nanopore Technologies6.107 Panagene6.108 Perkin Elmer6.109 Personal Genome Diagnostics6.110 Personalis6.111 Precipio6.112 PrecisionMed6.113 Promega6.114 Qiagen Gmbh6.115 Rarecells SAS6.116 RareCyte6.117 Roche Molecular Diagnostics6.118 Screencell6.119 Sense Biodetection6.120 Serametrix6.121 Siemens Healthineers6.122 Silicon Biosystems6.123 simfo GmbH6.124 Singlera Genomics Inc6.125 Singulomics6.126 SkylineDx6.127 Stratos Genomics6.128 Sysmex Inostics6.129 Tempus Labs, Inc6.130 Thermo Fisher Scientific Inc6.131 Thrive Earlier Detection6.132 Todos Medical6.133 Trovagene6.134 Variantyx6.135 Volition6.136 Vortex Biosciences

7 The Global Market for Cancer Gene Panels and Profiles7.1 Global Market Overview by Country7.2 Global Market by Cancer Type - Overview7.3 Global Market by Application - Overview7.4 Global Market by Tissue - Overview7.5 Global Market Germline & Somatic - Overview

8 Global Cancer Gene Panels & Profiles Markets - By Type of Cancer8.1 Comprehensive Panels & Profiles8.1.1 Table Comprehensive Testing - by Country8.1.2 Chart - Comprehensive Testing Growth8.2 Breast Cancer Gene Testing8.2.1 Table Breast Cancer Gene Testing - by Country8.2.2 Chart - Breast Cancer Testing Growth8.3 Colorectal Cancer Gene Testing8.3.1 Table Colorectal Cancer Gene Testing - by Country8.3.2 Chart - Colorectal Cancer Gene Testing Growth8.4 Gynecological Cancer Gene Testing8.4.1 Table Gynecological Cancer Gene Testing - by Country8.4.2 Chart - Gynecological Cancer Gene Testing Growth8.5 Blood Cancer Gene Testing8.5.1 Table Blood Cancer Gene Testing - by Country8.5.2 Chart - Blood Cancer Gene Testing Growth8.6 Prostate Cancer Gene Testing8.6.1 Table Prostate Cancer Gene Testing - by Country8.6.2 Chart - Prostate Cancer Testing Growth8.7 Lung Cancer Gene Testing8.7.1 Table Lung Cancer Gene Testing - by Country8.7.2 Chart - Lung Cancer Gene Testing Growth8.8 Other Cancer Gene Testing8.8.1 Table Other Cancer Gene Testing - by Country8.8.2 Chart - Other Cancer Gene Testing Growth

9 Global Cancer Gene Panels & Profiles Markets - By Type of Application9.1 Clinical Testing9.1.1 Table Clinical Testing - by Country9.1.2 Chart - Clinical Testing Growth9.2 Pharmaceutical Testing9.2.1 Table Pharmaceutical Testing - by Country9.2.2 Chart - Pharmaceutical Testing Growth9.3 Research Testing9.3.1 Table Research Testing - by Country9.3.2 Chart - Research Testing Growth

10 Global Cancer Gene Panels & Profiles Markets - By Tissue Type10.1 Solid Tissue10.1.1 Table Solid Tissue Testing - by Country10.1.2 Chart - Solid Tissue Testing Growth10.2 Liquid Tissue Testing10.2.1 Table Liquid Tissue Testing - by Country10.2.2 Chart - Liquid Tissue Testing Growth

11 Global Cancer Gene Testing Markets - Germline and Somatic11.1 Global Market Somatic11.1.1 Table Somatic - by Country11.1.2 Chart - Somatic Testing Growth11.2 Global Market Germline11.2.1 Table Germline - by Country11.2.2 Chart - Germline Testing Growth

12 Potential Market Opportunity Sizes12.1 Potential Cancer Screening by Country: Lung, Breast & Colorectal12.2 Potential Cancer Screening by Country: Prostate, Other Cancer & All Cancer12.3 Potential Market Size - Cancer Diagnosis12.4 Potential Market Size - Therapy Selection

13 Appendices

For more information about this report visit https://www.researchandmarkets.com/r/ybmn5m

Read more from the original source:
Insights on the Genomic Cancer Panel and Profiling Global Market to 2025 - GlobeNewswire

Recommendation and review posted by Bethany Smith

Global Animal Genetics Market 2021-2025 The analyst has been monitoring the animal genetics market and it is poised to grow by $ 1. 84 bn during 2021-2025, progressing at a CAGR of almost 7% during the forecast period.

New York, July 05, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Animal Genetics Market 2021-2025" - https://www.reportlinker.com/p06102913/?utm_source=GNW Our report on animal genetics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the growing consumption of animal-derived food products and growing demand for genetic testing services to reduce livestock diseases. In addition, growing consumption of animal-derived food products is anticipated to boost the growth of the market as well.The animal genetics market analysis includes solution segment and geographic landscape.

The animal genetics market is segmented as below:By Geography North America Europe Asia ROW

By Solution Live animal Genetic testing services Genetic materials

This study identifies the growing focus on research and development in animal genomics as one of the prime reasons driving the animal genetics market growth during the next few years.

The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on animal genetics market covers the following areas: Animal genetics market sizing Animal genetics market forecast Animal genetics market industry analysis

This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading animal genetics market vendors that include Animal Genetics Inc., AquaGen AS, Aviagen Inc., Cooperatie Koninklijke CRV u.a., Genetic Veterinary Sciences Inc, Genus Plc, Hendrix Genetics BV, Neogen Corp., Topigs Norsvin Holding B.V., and Zoetis Inc. Also, the animal genetics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavios market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.Read the full report: https://www.reportlinker.com/p06102913/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Continued here:
The Global Animal Genetics Market is expected to grow by $ 1.84 bn during 2021-2025, progressing at a CAGR of almost 7% during the forecast period -...

Recommendation and review posted by Bethany Smith

SAN DIEGO, July 02, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that Chief Medical Officer Dr. Alka Chaubey and current President of the Cancer Genomics Consortium Dr. Yassmine Akkari will present at the 6th Annual International Conference of the Board of Genetic Counseling India to be held virtually from July 2nd-4th 2021. Dr. Chaubey has been recognized to present as an invited speaker and will discuss how optical genome mapping (OGM) is enabling a revolution in cytogenetics during a session titled Genetic Counseling in the Omics Era on Saturday July 3rd at 9:25 am IST. Dr. Akkari will present her results using OGM for the genome analysis of Acute Myelogenous Leukemia (AML), and discuss how genetic counselors can introduce OGM to patients on July 3rd at 4:10 pm IST. Bionano Genomics is a Diamond Sponsor of the conference.

This conference aims to promote education among genetic counselors, specialists, doctors, health care providers and students, about current topics in genetics, genomics and genetic counseling. The Annual International Conference of the Board of Genetic Counseling India has over 2,000 delegates from across the globe and can be accessed at bgciconference.com

About Bionano GenomicsBionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. Bionanos Saphyr system is a research use only platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools. Bionano provides genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. Lineagen has been providing genetic testing services to families and their healthcare providers for over nine years and has performed over 65,000 tests for those with neurodevelopmental concerns. For more information, visit http://www.bionanogenomics.com or http://www.lineagen.com.

Story continues

CONTACTSCompany Contact:Erik Holmlin, CEOBionano Genomics, Inc.+1 (858) 888-7610eholmlin@bionanogenomics.com

Investor Relations and Media Contact:Amy ConradJuniper Point+1 (858) 366-3243amy@juniper-point.com

See the original post:
Bionano Genomics Chief Medical Officer Dr. Alka Chaubey and Cancer Genomics Consortium President Dr. Yassmine Akkari to Present on Optical Genome...

Recommendation and review posted by Bethany Smith

Shahid Akhter, editor, ETHealthworld, spoke to Neeraj Gupta, Founder and CEO, Genes2me, to know more about the increased need for molecular diagnostics during the Cocvid-19 pandemic.

How has the molecular diagnostics market evolved in the last decade?The importance of Molecular Diagnostics have received significant recognition in last decade and with the emergence of Covid-19 pandemic in last 1 year, RTPCR tests have become common talking term in every house along with eruption in the Healthcare requirements. In order to cater huge requirements of RTPCR testing for Covid-19, numerous laboratories have adopted RTPCR and automated RNA Extraction platforms. Also, multiple Companies expanded their portfolio and ventured into IVD kits manufacturing as the demand increased for Made In India products.

Why there is a need for Advanced Molecular Diagnostics and Genetic testing segment?There has been increased need for Advanced Molecular Diagnostics and Genetic Tests due to increase in occurrence of Rare Genetic Disorders and new Infectious Diseases (like SARS-COV-2, Mucormycosis, etc.). Also as new strains of SARS-COV-2 are frequently being reported, importance of Advanced Genetic Testing gains significance. Recently, Genes2Me have also developed Unique Mutation Classifier assay which can rapidly differentiate 40 variants between 16 SARS-CoV-2 strains allowing quick genetic screening of large sections of population.What has been the role of technology in enhancing India's testing condition during this pandemic?With the emergence of Covid-19, the need of Molecular Diagnostics have been recognised and grown in last 1 year with spread of network of RTPCR and Automated RNA Extraction Instruments across India. It has really helped in ramping the testing for Diagnosing positive cases on time. Genes2Me is also aggressively working to leverage this massive installed base of Genetic Testing platforms. Based on our expertise in Genomics and access to latest Technologies, we have been able to develop several assays for Infectious diseases, Oncology and Reproductive Health in India. Most of these test panels have been Import dependent from other countries. Similarly, Genes2Me team is aggressively working to develop diverse range of Research and Diagnostics Solutions for Nucleic Acid testing along with Next Generation Sequencing reagents for Genome sequencing.

Genes2Me is committed to continuously deliver Innovative and scientific solutions such as much needed Unique Mutation Classifier assay for SARS-COV-2 strain and easy self-use Antigen test kits solutions which is under R&D phase, besides many other products.

***

Read more from the original source:
Emergence of new strains of SARS-COV-2, paves the way for Advanced Genetic Testing: Neeraj Gupta, Genes2me - ETHealthworld.com

Recommendation and review posted by Bethany Smith

I am nominating Lily Apfel, LVN, for the Extraordinary Healer Award. I came to know Lily in 2015 when she was diagnosed with breast cancer at the age of 35. She was a LVN working at our gastroenterology clinic. She was under my care and received comprehensive treatment including surgery, chemotherapy and radiation. During the treatment, she showed great strength and handled the tough ordeals gracefully. Our staff loved her.

Half a year later, at one of her follow-up appointments, I recruited her, and she was extremely excited and has joined us since. For the ensuing years, she has taken important roles. I am a solo provider for this community, so our staff often take multiple roles to meet the complexity of oncology care. She is our liaison and go-to person on oncology-specialty oral drugs. She is our head person on genetic testing. She handles our tumor board logistics.

There are also other attributes that make her unique. She is a great patient advocate, especially for uninsured Hispanics in our community. Lily is fluent in Spanish, and she is almost the only person these patients depend on to get their oncology care coordinated and drugs covered. She would go beyond for those patients. Lily is also very active in her own community, which is different from where she is working. It is not uncommon to hear that she does house hospice visits.

Please consider her for this Extraordinary Healer Award. Our clinic and community are very fortunate to have her.

Editors Note: This is an essay submitted by Dr. Hengbing Wang for the 2021 Extraordinary Healer Award. Click here to read more about CUREs Extraordinary Healer Award for Oncology Nursing event on April 30, 2021.

For more news on cancer updates, research and education, dont forget tosubscribe to CUREs newsletters here.

More here:
Impacting Communities Around Her as a Patient and Nurse - Curetoday.com

Recommendation and review posted by Bethany Smith

Amyotrophic lateral sclerosis, better known as ALS or Lou Gehrig's disease, is a rare neurological disorder that that approximately 20,000 U.S. residents are living with during any given year. And while your chances of receiving an ALS diagnosis may be relatively low, the prognosis for people with ALS is dire. According to the Centers for Disease Control and Prevention (CDC), patients with ALS typically live just two to five years after first displaying symptoms, which typically include muscle weakness or stiffness, spasms, fatigue, and difficulty swallowing, among others.

Researchers know that these symptoms arise due to the disease attacking motor neurons in the brain and spinal cord which are needed for muscle movement, but the root cause of ALS is still unfortunately unknown. Experts say that both genetic and environmental factors likely play a role. In fact, there's one genetic factor that may give you an insight into your risk level. Read on to discover the one thing 90 percent of people with ALS have have in common.

RELATED:If You Notice This in the Morning, It May Be an Early Sign of Parkinson's.

According to the ALS Association (ALSA), roughly 90 percent of patients have "sporadic ALS," a type of ALS that is not inherited through genetic mutations. In these cases, the person diagnosed is the only person in their family with the disease. The onset of their disease typically occurs later than it does in patients with a known family history of ALS.

RELATED:If You Do This at Night, It May Be an Early Sign of Parkinson's, Study Says.

The remaining 10 percent of ALS cases are considered "familial ALS" (FALS). "In these cases, more than one person in the family has ALS and sometimes family members have frontotemporal dementia as well. People with FALS often start showing symptoms at earlier ages than in sporadic ALS," writes Deborah Hartzfeld, MS, a certified genetic counselor (via the ALSA).

This statistic can spur confusion for some about one's odds of developing ALS depending on family history. While nine out of 10 people with ALS will have no known family history, you're much more likely to develop ALS if you've got a family history of the disease than if you do not.

The FALS gene mutation is most often autosomal dominant, meaning only one parent must have it in order to pass it onto their children. It also means that the affected parent has one copy of the gene with a mutation and one without, meaning they have a 50 percent chance of passing it the mutation on to their offspring.

According to the ALS Association, "typically, although not always, there will be someone in each generation with ALS and/or dementia," which appears alongside ALS in one third of cases. It is worth noting that not everyone with the genetic mutation will go on to develop symptoms of ALS.

For more health news sent directly to your inbox, sign up for our daily newsletter.

Though 90 percent of ALS cases are not the result of an inherited genetic mutation, genetic screening can help you better understand your risk if you do have a family history. This will typically require either a blood or saliva test, and can take several months to get results. The results can only be interpreted if the person in your family diagnosed with ALS is also able to participate in testing.

However, the ALSA points out that even with genetic testing, you cannot rule out the possibility of passing on familial ALS. "Not having an identified genetic mutation does not eliminate a FALS diagnosis and other family members may still be at risk for developing ALS," the organization explains. Speaking with your doctor is the first and most important step to find out your personal riskespecially if you're presenting with any possible ALS symptoms.

RELATED:This Is The Single Best Way to Predict Your Heart Attack Risk, Experts Say.

Link:
90 Percent of People With ALS Have This in Common, Experts Say - Best Life

Recommendation and review posted by Bethany Smith

New Jersey, United States,-The report titled Predictive Genetic Testing And Consumer/Wellness Genomics Market is a comprehensive document containing valuable insights into market elements such as drivers, restraints, competitive landscape, and technology development. The report offers a comprehensive analysis of key segments and future growth prospects for a better understanding of the market. The current COVID-19 pandemic has seriously altered market dynamics and the global economy. The report includes an analysis of the impact of the pandemic on the global market. It also provides current and future impact studies. The report provides a comprehensive analysis of the dynamic changes in trends and demands due to the COVID-19 pandemic. The report also contains a post-COVID scenario and prospects for future growth.

Competitive analysis includes key players and the innovations and business strategies they have implemented. The report captures the best long-term growth opportunities for the industry and includes the latest process and product developments. The report provides basic information of the companies along with their market position, history, market capitalization, and revenue. The report includes the sales figures, market growth rate and gross profit margin of each player based on regional classification and overall market position. The report provides a separate analysis of recent business strategies such as mergers, acquisitions, product launches, joint ventures, partnerships and collaborations.

Get | Download Sample Copy with TOC, Graphs & List of Figures @https://www.verifiedmarketreports.com/download-sample/?rid=472815

Key Features of the Report:

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include:

Illumina BGI Genesis Genetics Myriad Genetics 23andMe Inc Color Genomics Inc Pathway Genomics ARUP Laboratories

The report provides valuable insights into the advancement of the Predictive Genetic Testing And Consumer/Wellness Genomics market and related approaches to the Predictive Genetic Testing And Consumer/Wellness Genomics market with an analysis of each region. The report also discusses the dominant aspects of the market and examines each segment.

Market Breakdown:

The market breakdown provides market segmentation data based on the availability of the data and information. The market is segmented on the basis of types and applications.

The report further studies the market segmentation based on the types of products offered in the market and their end-uses/uses.

Predictive Testing Consumer Genomics Wellness Genomics

By the application, this report covers the following segments:

Breast & Ovarian Cancer Cardiovascular screening Diabetic Screening & Monitoring Colon Cancer

Get Discount On The Purchase Of This Report @https://www.verifiedmarketreports.com/ask-for-discount/?rid=472815

Predictive Genetic Testing And Consumer/Wellness Genomics Market Report Scope

To understand the Predictive Genetic Testing And Consumer/Wellness Genomics market dynamics, the market is analyzed across major global regions and countries. Verified Market Reports provides customized specific regional and country-wise analysis of the key geographical regions as follows:

North America:USA, Canada, Mexico

Latin America:Argentina, Chile, Brazil, Peru, and Rest of Latin America

Europe:UK, Germany, Spain, Italy, and Rest of EU

Asia-Pacific:India, China, Japan, South Korea, Australia, and Rest of APAC

Middle East & Africa:Saudi Arabia, South Africa, U.A.E., and Rest of MEA

Key Elements Addressed in the Report:

Market Scenario:

The report highlights the essential features of the business sphere of the Predictive Genetic Testing And Consumer/Wellness Genomics industry. It covers development trends, factors driving the growth of the market, and segments influencing the growth of the market. It covers the product types, applications, types, deployments, and developments happening in the market.

Market Highlights:

The report provides an in-depth analysis of the market involving key elements, revenue estimations, cost analysis, import/export, production and consumption trends, CAGR, gross margin, and supply & demand patterns. The report further gives an idea about the development factors and advancement patterns of the Predictive Genetic Testing And Consumer/Wellness Genomics industry.

Analytical Tools:

The Predictive Genetic Testing And Consumer/Wellness Genomics Market is assessed through extensive primary and secondary research, which is further validated and verified by industry experts and professionals. The report examines key players operating in the market along with their market position, market share, revenue, gross margin, and business strategies. SWOT analysis and Porters Five Forces Analysis are conducted to examine and assess the market and its players. Moreover, the report also offers a feasibility study and investment return analysis to assist the readers in making strategic investment plans.

How will the report help your business grow?

? This document provides statistics on the value (in USD) and size (in units) of the Predictive Genetic Testing And Consumer/Wellness Genomics industry from 2021 to 2028.

? The report also details major competitors in the market that will have a greater impact on Predictive Genetic Testing And Consumer/Wellness Genomicss business.

? Comprehensive understanding of the fundamental trends affecting each sector despite the greatest threat, the latest technologies and opportunities that can create a global Predictive Genetic Testing And Consumer/Wellness Genomics market for both supply and demand.

? The report will help the client identify the key results of the major market players or rulers of the Predictive Genetic Testing And Consumer/Wellness Genomics sector.

For More Information or Query or Customization Before Buying, Visit @https://www.verifiedmarketreports.com/product/predictive-genetic-testing-and-consumer-wellness-genomics-market-size-and-forecast/

Visualize Predictive Genetic Testing And Consumer/Wellness Genomics Market using Verified Market Intelligence:-

Verified Market Intelligence is our BI-enabled platform for narrative storytelling of this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue-impacting decisions for a brilliant future.

VMI provides a holistic overview and global competitive landscape with respect to Region, Country, and Segment, and Key players of your market. Present your Market Report & findings with an inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D, and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.

Visualize Predictive Genetic Testing And Consumer/Wellness Genomics Market using VMI @https://www.verifiedmarketresearch.com/vmintelligence/

About Us: Verified Market Reports

Verified Market Reports is a leading Global Research and Consulting firm servicing over 5000+ global clients. We provide advanced analytical research solutions while offering information-enriched research studies.

We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Our research spans over a multitude of industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverages etc. Having serviced many Fortune 2000 organizations, we bring a rich and reliable experience that covers all kinds of research needs.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (753)-715-0008APAC: +61 (488)-85-9400US Toll-Free: +1 (800)-782-1768

Email: sales@verifiedmarketreports.com

Website: https://www.verifiedmarketreports.com/

Go here to see the original:
Predictive Genetic Testing And Consumer/Wellness Genomics Market Size and Growth 2021-2027 | Top Manufacturers Illumina, BGI, Genesis Genetics,...

Recommendation and review posted by Bethany Smith

Genetic testing, or more specifically pharmacogenomics, plays an important role by enabling healthcare providers to more accurately predict which treatments will work well, as well as which drugs may lead to unwanted side effects.

In the case of cancer treatments, it is also possible to look at the genome of the tumour itself to see which therapies are most likely to be effective. The Clinical Pharmacogenetics Implementation Consortium (CPIC) is an international group dedicated to facilitating the use of pharmacogenomic testing for patient care. One such example of this is dihydropyrimidine dehydrogenase (DPD) enzyme deficiency screening, by way of DPYD gene testing. Yourgene Health are proud to be supporting the international roll out of this screening to the benefit of millions of patients undergoing treatment for cancer.

Fluoropyrimidines such as 5-Fluorouracil (5-FU) and its prodrugs capecitabine and tegafur are chemotherapy agents widely used in the treatment of patients with gastrointestinal (GI), head/neck, breast, and other forms of solid tumour cancer. Only a fraction of a fluoropyrimidine drug is transformed into active cytotoxic agents. The dihydropyrimidine dehydrogenase (DPD) enzyme is necessary to catabolise most of these agents to inactive products, thus limiting the circulating levels of fluoropyrimidines. When DPD enzyme activity is deficient, patients treated with standard dosing of fluoropyrimidines are at significantly increased risk of severe toxicities or even death. The DPYD gene encodes for the synthesis of the DPD enzyme. DPD enzyme deficiency is strongly correlated with certain variants in the DPYD gene.

Fluoropyrimidines-based chemotherapy is used to treat over two million patients every year across the world. 3-8% of individuals are believed to be carriers of one or more known risk variants in DPYD gene. Carriers of a causative variant are at up to an 88% risk of severe toxicity if treated with a standard dose. DPYD testing helps identify those individuals who are at increased risk of these toxic side effects. These patients can be offered alternative therapies or lower treatment doses. The CPIC has issued guidance on dosage modifications recommended for a select number of genotypes and their associated activity score. Pre-emptive genotyping of all patients for these specific variants has proven highly precise in predicting an adverse drug response, with a specificity of ~95%.

Late last year NHS England announced that all at-risk cancer patients (approximately 38,000 each year) will now routinely be tested for DPYD variants. The Elucigene DPYD assay is already in use across multiple laboratories in several English Genomic Laboratory Hubs, including Liverpool and Cambridge.

The assay is also being used to provide nation-wide testing in Wales following a successful pilot programme with All Wales Medical Genomics Service (AWMGS), and for Scotland in within the Genetic Consortium Laboratories. In Wales alone, the test is used to screen approximately 200 patients each month. If the screen positive rate of 6% identified in the pilot continues, we anticipate 144 cancer patients will be prevented from having toxic chemotherapy reactions over the next year.

Please note: This is a commercial profile

2019. This work is licensed under aCC BY 4.0 license.

Editor's Recommended Articles

See the original post:
DPYD genotyping to improve patients' therapy response - Open Access Government

Recommendation and review posted by Bethany Smith

This piece originally appeared on the Good Notes blog.

Virtual health care is here to stay. Many believe the era of telehealth was launched by the coronavirus pandemic. It wasnt, but the health crisis certainly accelerated it. Prior to the pandemic, 2% of University of Utah Health providers had seen patients virtuallynow, 90% have. From March 2020 to March 2021, our providers held 400,000 virtual telehealth sessions. That amounts to between 6,000 and 8,000 sessions a week.

Telehealth will continue to evolve. It already involves more than live transmission of a patients face onto a providers device while the patient describes his or her state of health and asks questions. As diagnostics continue to improve, patients will be able to do more within their own homes. Wearable medical devices are increasingly integrated with remote care delivery. Remote labs continue to emerge, changing how patients monitor their health. Think of swabs that patients collect in the comfort of home and drop into a mailbox for analysis. This exists for genetic testing companies like 23andMe. We did it with COVID-19 tests. Coronavirus testing advanced quite rapidly so that someone at home could do a self-swab and send it back to a central lab.

For more complex lab diagnostics, imagine the day when a lab technician comes to your home to collect samples for testing or perform imaging tests like an X-ray. The idea is to flip the supply chain upside down: Instead of the patient coming to the hospital, lab or imaging center, why not the hospital, lab, or imaging center going to the patient?

The premise of all these things is making health care more convenient, easier to access, and ultra-consumer-centered. Delivery in the home, or wherever it may be convenient for the patient, is a rapidly expanding trend. Video visits are just one component of it. Certain visits still need hands-on evaluation, often with a video component. From my perspective as an orthopaedist, we had to develop a structure for telehealth sessions to be effective. We now have a short video we send to patients ahead of time that tells them the multiple steps they should take before treatment. For a new patient appointment, I need the patient to make certain videos and take certain photographs of themselves to send in, before I see them virtually. My colleagues and I intend to streamline virtual visits even more because its incredibly cost-effective and time-effective for the patient.

Telehealth also means better access to care and treatment at U of U Health for our patient base geographically spread across the Mountain West and beyond. We have one of the most rural populations of a major academic medical center anywhere in the country. Virtual care gives us a chance to reach out, talk to, and evaluate patients across broad geography without them needing to leave their homes or burn carbon fuels. It gets us even closer to University of Utah Healths goal of providing our regional population with access to world-class patient-centered care.

With telehealths initial success and great potential, its still not for everyonenor effective for every condition. Many patients remain skeptical about virtual visits, thinking their physician may not get an accurate picture or full understanding of their health issue. There are also patients who just find comfort and reassurance from in-person conversations. We need to give patients choice. As long as it is clinically appropriate, telehealth works wellespecially when we match the right circumstances to a patients preference.

Our data shows that whats wanted is as varied as our patient populations. A core group of more digitally literate patients quickly recognized the benefits of virtual care. Most of these patients connect to us with their smartphones. They are motivated to learn quickly because digital technology connects with their physicianand helps them bring in family members from dispersed locations to participate in health care visits. Yet theres a huge swath of our patient population that hasnt had enough digital experience to be comfortable talking device to device.

The telehealth option is increasingly widespread. Its not just at U of U Health, an academic health organization with state-of-the-art digital equipment, where the reconfigured world of patient care is underway. Traditional health care business models of all sizes are expanding home-based clinical care. Coalitions have formed among health care groups to support policy changes that designate the home as a site of clinical service.

With vaccinations and the number of COVID cases falling during the last couple of months, theres been an appropriate decrease in virtual care within our system. But it has not returned to pre-COVID levels. It is here to stay. So our mission in approaching the new normal is to pivot and be especially strategic about virtual care to ensure that we use it to meet the needs of our patients. Whenever possible, we also want to offer the deep resources of our academic tertiary health care system. We need to maintain exceptional value with high standards of quality and experience for patients and providers.

More:
Here to stay: The era of telehealth | @theU - @theU

Recommendation and review posted by Bethany Smith

The Latest Direct to consumer Genetic Testing Market report helps to identify the growth factors and business opportunities for the new entrants in the Global Direct to consumer Genetic Testing industry with a detailed study of Market Dynamics and technological innovations and trends of the Global Direct to consumer Genetic Testing Market. The report covers all leading vendors operating in the market and the small vendors which are trying to expand their business at a large scale across the globe. That report presents strategic analysis and ideas for new entrants using a historic data study. The study report offers a comprehensive analysis of market share in terms of percentage share, gross premium, and revenue of major players functioning in the industry of the Global market. Thus, the report provides an estimation of the market size, revenue, sales analysis, and opportunities based on the past data for current and future market status.

This research report offers PESTEL analysis, Porters Five Force Analysis, and Ecosystem analysis of the Global Direct to consumer Genetic Testing Market. Furthermore, the research report covers all the major countries and regions which have a good market scale of different vendors in those regions. Also, the report forecasts the market size of the Global Direct to consumer Genetic Testing Market in Compound Annual Growth Rate in terms of revenue during the forecast period. The research report also offers in-depth analysis about the Agreements, collaboration, and partnership among different vendors across the globe to expand the business of the Global Direct to consumer Genetic Testing Market.

Request for a sample copy of the report to get extensive insights into Direct to consumer Genetic Testing market and Get Upto 30% Discount at https://www.in4research.com/sample-request/48195

Top listed Players for Global Direct to consumer Genetic Testing Market are:

How has the competitive landscape of this industry been categorized?

Direct to consumer Genetic Testing Market Segmentation by Type, Application, and Region as follows:

By Type:

By Application:

Geographically, this report is segmented into several key Regions along with their respective countries, with production, consumption, revenue, and market share and growth rate of Direct to consumer Genetic Testing in the following regions:

For more Customization, Connect with us at https://www.in4research.com/customization/48195

Valuable Points Covered in Direct to consumer Genetic Testing Research Study are:

Reasons to Access Direct to consumer Genetic Testing Market Report:

Buy Full Research Report at https://www.in4research.com/buy-now/48195

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:

Contact Name: Rohan

Email: contactus@in4research.com

Phone: +1 (407) 768-2028

Original post:
Direct to consumer Genetic Testing Market Research Insight 2021 Complete Overview & Qualitative Analysis by Major Companiess like 23andMe,...

Recommendation and review posted by Bethany Smith

Nonacus, a provider of genetic testing products for precision medicine and liquid biopsy, and the University of Birmingham have partnered to develop a non-invasive test for bladder cancer. The test, which is expected to be available by mid-2022, will use highly sensitive liquid biopsy technology developed by Nonacus, and a panel of biomarkers validated by Dr. Rik Bryan and Dr. Douglas Ward from the Universitys Bladder Cancer Research Centre, to diagnose the disease from urine samples.

Bladder cancer is the seventh most common cancer in the developed world. In the UK, over 100,000 people a year are referred to hospital clinics that investigate for bladder cancer, usually after passing blood in their urine (haematuria). The first stage of investigation is usually cystoscopy, which involves inserting a camera into the bladder. Of these 100,000 patients, around 12% are subsequently diagnosed with bladder cancer, normally after a second invasive procedure to extract a biopsy.

Dr. Bryan, Director of the Bladder Cancer Research Centre, commented: While blood visible in the urine should always be investigated, over 80% of people who have a cystoscopy at a haematuria clinic are diagnosed with non-malignant conditions or have no abnormality. Unfortunately, the remaining 20% will need a further invasive procedure to confirm a diagnosis. What is required is a highly sensitive and specific, non-invasive test that can rapidly determine those who need a biopsy and those who do not, and a urine test is the obvious place to start.

While the liquid biopsy approach is attractive, the low levels of tumor DNA in a background of DNA from normal tissues require highly sensitive analytical techniques to obtain accurate results. However, researchers at the University started their work in the knowledge that Nonacus had successfully pioneered commercial non-invasive prenatal tests to identify low levels of fetal DNA in maternal blood samples. Moreover, the company was developing methods to allow confident and sensitive calling of mutations from as little as 10ng of DNA.

The researchers used deep sequencing of tumor DNA to identify mutations that are present in the majority of urothelial bladder cancers (UBCs). Their work, which was funded by Cancer Research UK and an MRC Confidence in Concept grant, involved sequencing 23 genes from tumor samples collected from 956 newly diagnosed, treatment-nave patients. This deep sequencing of genes identified 451 unique mutations that were present in over 96% of tumors. The researchers also demonstrated that these mutations were identifiable in urine samples collected at the same time as tumor sampling.

As the researchers have shown, mutated DNA in a urine sample can be extracted from cancer cells shed into the urine from the lining of the urinary tract or can be found as cell-free DNA fragments2. However, extracting DNA from the cancer cells provides more reliable amounts of DNA for the test, especially when only small volumes of urine may be available. Coupling the mutation panel with the unique molecular identifiers and the proprietary target capture technology provided by the Nonacus Cell3 Target will provide a much more sensitive test than the existing PCR-based approach. The researchers are already working on validating this combination in a further 600 cases (including non-cancer cases) and they expect to publish data on sensitivity and specificity within six months.

Nonacus intends to launch the new bladder cancer test within 12 months, and the final product will include access to bioinformatics software to help with analysis. The company expects the test will provide high sensitivity for all stages and grades of disease and will ensure the test is available worldwide to laboratories, hospitalsand clinics.

Promisingly, the original research also determined the influence of the mutations on cancer progression, time to recurrence, and overall and disease-specific survival in patients with non-muscle-invasive bladder cancer (NMIBC), and disease-specific survival in patients with muscle-invasive bladder cancer (MIBC), raising the possibility that the test could be used to stratify patients according to risk.

Chris Sale, CEO of Nonacus, commented: We expect this partnership to deliver better care and outcomes for patients by reducing the number of invasive procedures, providing earlier diagnosis and speeding up access to treatment for people with bladder cancer.

Tony Hickson, Chief Business Officer at Cancer Research UK, said: "As funders of much of the world-class, cutting-edge cancer research happening in the UK, we offer unique opportunities to commercial partners looking for early involvement in new discoveries. Having Nonacus on board to help transform promising findings in the lab into a new non-invasive test to diagnose bladder cancer is a testament to how commercial collaborations have the potential to transform the lives of patients. We are looking forward to seeing the next steps as the test is developed and rolled out to the UK and beyond.

Allen Knight, Chair of Trustees, Action Bladder Cancer UK, said: This really is very exciting and has the potential to make an incredible difference for patients and for Bladder Cancer treatment. Currently, urine tests do not accurately pick up bladder cancer, and invasive tests are required to confirm a diagnosis. A urine test that can rapidly determine who needs these tests will be a very welcome development. Many patients, myself included, find cystoscopies very uncomfortable at best, and they can have lasting side effects. This research could pave the way for routine screening, common in other cancers, but unavailable at present for Bladder Cancer."

For more of the latest science news, straight to your inbox, become a member of SelectScience for free today>>

Read the original here:
Birmingham University and Nonacus partnership - SelectScience

Recommendation and review posted by Bethany Smith

FACTS AT A GLANCEEdition:9;Released:April 2021Executive Engagements:1737Companies:51 - Players covered include Axol Bioscience Ltd.; Cynata Therapeutics Limited; Evotec SE; Fate Therapeutics, Inc.; FUJIFILM Cellular Dynamics, Inc.; Ncardia; Pluricell Biotech; REPROCELL USA, Inc.; Sumitomo Dainippon Pharma Co., Ltd.; Takara Bio, Inc.; Thermo Fisher Scientific, Inc.; ViaCyte, Inc. and Others.Coverage:All major geographies and key segmentsSegments:Cell Type (Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells, Other Cell Types); Research Method (Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering, Other Research Methods); Application (Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine, Other Applications)Geographies:World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World.

Complimentary Project Preview -This is an ongoing global program. Preview our research program before you make a purchase decision. We are offering a complimentary access to qualified executives driving strategy, business development, sales & marketing, and product management roles at featured companies. Previews provide deep insider access to business trends; competitive brands; domain expert profiles; and market data templates and much more. You may also build your own bespoke report using our MarketGlass Platform which offers thousands of data bytes without an obligation to purchase our report.Preview Registry

ABSTRACT-

Global Induced Pluripotent Stem Cell ((iPSC) Market to Reach $2.3 Billion by 2026Induced pluripotent stem cells (iPSCs) hold tremendous clinical potential to transform the entire therapeutic landscape by offering treatments for various medical conditions and disorders. These cells are derived from somatic cells like blood or skin cells that are genetically reprogrammed into embryonic stem cell-like state for developing an unlimited source of a diverse range of human cells for therapeutic applications. The global market is propelled by increasing demand for these cells, rising focus on researchers in the field, and their potential application in treatment of various diseases. The market growth is supplemented by rising prevalence of several chronic disorders such as diabetes, heart disease, stroke and cancer. Moreover, increasing awareness about stem cells and associated research, potential clinical applications and rising financial assistance by governments and private players are expected to contribute significantly to the market expansion. The iPSC technique is anticipated to find extensive adoption in the pharmaceutical industry for developing efficient cell sources like iPSC-derived functional cells to support drug screening and toxicity testing.

Amid the COVID-19 crisis, the global market for Induced Pluripotent Stem Cell ((iPSC) estimated at US$1.6 Billion in the year 2020, is projected to reach a revised size of US$2.3 Billion by 2026, growing at a CAGR of 6.6% over the analysis period. Vascular Cells, one of the segments analyzed in the report, is projected to record a 7.2% CAGR and reach US$835.8 Million by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Cardiac Cells segment is readjusted to a revised 7.9% CAGR for the next 7-year period. The demand for iPSC-derived cardiac cells is attributed to diverse applications including cardiotoxicity testing, drug screening and drug validation along with metabolism studies and electrophysiology applications.

The U.S. Market is Estimated at $767.1 Million in 2021, While China is Forecast to Reach $82.4 Million by 2026The Induced Pluripotent Stem Cell ((iPSC) market in the U.S. is estimated at US$767.1 Million in the year 2021. China, the world`s second largest economy, is forecast to reach a projected market size of US$82.4 Million by the year 2026 trailing a CAGR of 8.5% over the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.5 % and 6.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.5% CAGR. North America leads the global market, supported by continuing advances related to iPSC technology and access to functional cells used in pre-clinical drug screening. The market growth is supplemented by increasing insights into the iPSC platform along with high throughput analysis for drug toxicity. The iPSC market in Asia-Pacific is estimated to post a fast growth due to increasing R&D projects across countries like Australia, Japan and Singapore.

Neuronal Cells Segment to Reach $336.9 Million by 2026In the global Neuronal Cells segment, USA, Canada, Japan, China and Europe will drive the 6.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$202.9 Million in the year 2020 will reach a projected size of US$308 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$19.8 Million by the year 2026. More

MarketGlass PlatformOur MarketGlass Platform is a free full-stack knowledge center that is custom configurable to today`s busy business executive`s intelligence needs! This influencer driven interactive research platform is at the core of our primary research engagements and draws from unique perspectives of participating executives worldwide. Features include - enterprise-wide peer-to-peer collaborations; research program previews relevant to your company; 3.4 million domain expert profiles; competitive company profiles; interactive research modules; bespoke report generation; monitor market trends; competitive brands; create & publish blogs & podcasts using our primary and secondary content; track domain events worldwide; and much more. Client companies will have complete insider access to the project data stacks. Currently in use by 67,000+ domain experts worldwide.

Our platform is free for qualified executives and is accessible from our website http://www.StrategyR.com or via our just released mobile application oniOSorAndroid

About Global Industry Analysts, Inc. & StrategyRGlobal Industry Analysts, Inc., (www.strategyr.com) is a renowned market research publisher the world`s only influencer driven market research company. Proudly serving more than 42,000 clients from 36 countries, GIA is recognized for accurate forecasting of markets and industries for over 33 years.

CONTACTS:Zak AliDirector, Corporate CommunicationsGlobal Industry Analysts, Inc.Phone: 1-408-528-9966www.StrategyR.comEmail: [emailprotected]

LINKSJoin Our Expert Panelhttps://www.strategyr.com/Panelist.asp

Connect With Us on LinkedInhttps://www.linkedin.com/company/global-industry-analysts-inc./

Follow Us on Twitterhttps://twitter.com/marketbytes

Journalists & Media[emailprotected]

SOURCE Global Industry Analysts, Inc.

http://www.strategyr.com

Excerpt from:
Global Induced Pluripotent Stem Cell (iPSC) Market to Reach $2.3 Billion by 2026 - PRNewswire

Recommendation and review posted by Bethany Smith

After a year under the hatch, this summer 2021, glowing, luminous and radiant is the go-to gorgeous look that American women want !

For whatever face you have to show the world today, moisturizing oil replenishes your skin, repairing damage from UV and boosting your natural glow with an astonishing amount of benefits- which is formulated to re-energize your look as it tones and refines pores. Many viewers have asked my expert advice on the best ways to approach and achieve a dewy summer complexion that will leave skin luminously smooth on the path to corporate ascension during business hours as well as summer social activities.

ADVERTISEMENT

In the summer, I can simply suggest that less is more. Radiant glow is the way to go with a delicate added dose of a real-to-the-feel modified bronzer and a fresh coral blush. This season, in addition to eating fruits and vegetables. drink lots of water to replenish the skin. Be mindful to get in a sweaty cardio sesh to increase blood flow and that healthy look from within which ultimately surfaces in the face to improve skin texture and tone for a natural radiant complexion.

Protect your skin from the sun:

As I mentioned earlier, I know everyone just wants to get out and see the world again but you must take protection from the sun. Bronzing face drops is your answer to a bronzed face without the risks of sun exposure. Integrated into your skincare routine your tan can now be customizable, buildable, and most importantly, fake, without looking fake.

Exfoliation is essential for smoothskin. I recommend to exfoliate once or twice a week to remove deadskincells and leaveskin glowing. This season, a unique blend of supercharged ingredients have been expertly formulated to deeply moisturize and restore the skins natural balance, revealing a clear and radiant glow.

If you're looking for a moisturizer with a luminous finish, then read below where I have curated a Forbes list of super-hydrating product offerings infused withtechnicall advanced hyaluronic acidand pearl articlesthat blur, reflect, and enhance your complexion to make you look instantly more radiant than ever!

+ Lux Unfiltered:

For a natural color and glow.

+ Lux UnfilteredNo.12 Bronzing Face Drops is your answer to a bronzed face without the risks of sun exposure. N12 seamlessly integrates into your skincare routine without disrupting your process or products. It is fragrance-free, non-comedogenic, compatible with all skin types, and loaded with antioxidants. Your tan is now customizable, buildable, and most importantly, fake, without looking fake. Recommended to mix with your desired number of drops with your face moisturizer and apply to clean skin.$42

AbsoluteJOI:

The new Daily Hydrating Moisturizing Cream is the first of its kind, a nutrient-rich 2-in-1 tinted ... [+] moisturizer specifically crafted for women of color for everyday use.

ADVERTISEMENT

AbsoluteJOI-The new Daily Hydrating Moisturizing Cream is the first of its kind, a nutrient-rich 2-in-1 tinted moisturizer specifically crafted for women of color for everyday use. The Daily Hydrating Moisturizing Cream leaves no white cast a common problem for people with melanin-rich skin. $42.00

AJ Crimson Beauty:

AJC Universal Finishing Powder in Toasted Cinnamon

AJ Crimson Beauty-AJ Crimson Beauty's Universal Finishing Powders are perfect for all skin tones. Great to use to set your makeup for a Matte or Semi Matte Skin Finish. Can Be Used to set Foundation, Concealer, Contour, Highlight or Tattoo cover! Available in a range of colors including Neutral Matte, Bamboo, Rick Umber and Toasted Cinnamon. $35

ADVERTISEMENT

Beauty Bakerie:

Swatches of the Beauty Bakerie InstaBake Aqua Glass Foundation in Shades 301N to 325N.

Beauty BakerieBeauty Bakerie always makes strides to be inclusive towards people of color and provides a wide shade range for all skin tones. Lack of darker shades in complexion products is a huge issue in the cosmetics industry, and Beauty Bakerie brings a revolutionary shade range to the table with the InstaBake Aqua Glass Foundation. The shades are listed from Dark to Light to put darker complexions first. $34.00

Bespoke:

Luxury CBD, but affordable for every budget.

ADVERTISEMENT

Bespoke-Manuka Honey and Bespokes Potent CBD, infused in one amazing product with an astonishing amount of benefits. The Manuka Honey + CBD cream for hands and body offers you the healing benefits of Manuka honey, the inflammatory and pain support of CBD, plus the soothing, calming properties of menthol extract. Bespoke sources our Manuka honey from New Zealand. But not all Manuka is equal. We source only the purest honey with an Ultra Premium Grade Unique Manuka Factor (UMF) of 15+. Youre getting exceptionally high-quality Manuka along with the superior CBD youve come to trust Bespoke Extracts for. This topical treatment will enhance your skincare regimen. Use sparingly on sore, dry skin, or when experiencing muscle or joint pain. Manuka Honey + CBD Cream will nourish your skin and provide supportive care to soft tissues. $59

Circumference:

The gentle cleanser is powered by olive leaf extract, derived from byproduct harvested in California ... [+] that would otherwise go to waste.

Circumference-The second formula born from our Waste-Not Sourcing Initiative - this gentle, versatile cleanser is powered by upcycled olive leaves, in partnership with California-made, Brightland. Last fall, we approached the modern essentials pantry brand to take the byproduct - that have no use in the olive oil making process - and slow-extract for bioactive nutrients in our labs. After the process was complete and we got the formula just right, mulch was returned to us for the following seasons compost - completing the circular economy. $48

ADVERTISEMENT

CocoBaba:

CocoBaba Coconut Butter Mousse, Coconut Body Oil, and Coconut Oil Scrub.

CocoBaba- CocoBaba is the new all-natural, vegan skincare line for women founded by Emma Heming Willis. CocoBaba was originally conceptualized when Emma was pregnant with her first daughter and was in search for an all-natural coconut oil-based product line to nourish and soothe her skin but could not find one. After 4 years in the making, the brand finally launched earlier this year and while its targeted toward moms and moms-to-be, its great for anyone! As summer approaches and we spend more time outside, its time to pay extra attention to our skin and make sure its nourished and protected to maintain that beautiful summer glow all season long!

All CocoBaba products are made with pure, certified organic coconut oil, and are 100% vegan, dermatologically tested, and completely free of silicones, parabens, and mineral oils. The Coconut Butter Mousse is a natural, effective way to nourish skin with this whipped blend of coconut, chia, sunflower, and jojoba oil. The Coconut Body Oil is silky but never greasy, this natural beauty secret uses 100% raw certified organic coconut oil to lock in moisture. And finally, the Coconut Oil Scrub is an all-natural exfoliant made with real coconut husk and apple seed. $54.99

ADVERTISEMENT

EiR NYC:

Surf Mud Body Oil

EiR NYC-As with all EiR suncare products, Surf Mud Body Oil is made with 100% Reef Safe Ingredients. Surf Mud Body Oil is a tinted tanning oil with Antioxidant-rich hydrating oil combined with zinc and chocolate to deeply moisturize and increase blood flow to the skin, and enhance your bronze-y sun-kissed look.$35

Elaluz:

ADVERTISEMENT

Camila never leaves home without her All Day Beauty Water and neither should you keep your skin ... [+] glowing and give it a refreshing boost on-the-go all summer long!

laluz-When Elaluz founder Camila Coelho created The All Day Beauty Water she knew she wanted a versatile product she could use throughout the day to keep her skin glowing and nourished. Enriched with Brazilian superfood ingredients like Guarana & Papaya Extracts and Buriti & Bataua Oils, this instant skin boost is formulated to re-energize your look as it tones and refines pores. Use it before makeup to prep, post-application to set, or whenever you need an instant boost of radiance. $49 USD

Hey Dewy:

Get the cutest, facial humidifier today - your skin and hair will thank you for it.

ADVERTISEMENT

Hey Dewy- Bring this portable USB humidifier with you wherever you go for continual hydration at your desk for work, overnight while you sleep or on-the-go to your dream destination. You can also nourish your skin with Hey Dewy before, after or even during your beauty routine. Our portable facial humidifier is our flagship product that is the foundation of our brand and purpose. It serves as the conduit to wellness via water and humidification, as well as the means to giving 10% to Clean Water initiatives like The Water Project. $39

Hydra Bloom:

Moonshine Coconut Illuminizer helps bring out your inner glow by adding a gorgeous highlight to your ... [+] cheekbones, eyes and decolletage.

Hydra Bloom-This skin perfector suits all skin tones. Made with Coconut and natural shimmering minerals and Vitamin E and Australian Flower Essences this illuminizer will have you glowing. $28.00

ADVERTISEMENT

James Read Tan:

Tan Easy-to-apply and can be tailored to your liking perfect to achieve that faux post-vacation ... [+] tan while quarantining.

James Read Tan-Concentrated onthe-go multi-vitamin gel tanning drops that you can add to your SPF or moisturizer. Formulated with powerful antioxidants and Vitamin complexes combined with key anti-ageing skincare ingredients to gently brighten, smooth and tan your skin. Formulated to improve the skins natural defense against free radicals, stimulate collagen synthesis and gives you a natural looking glow. Enriched with Vitamin C, Hyaluronic Acid, Aloe Vera, Natural Caramel and self-tan for the ultimate glow.$33

Kura Skin:

Kura Skin

ADVERTISEMENT

Kura Skin-Kura Skin curates clean, personalized skincare routines just for you. Kura analyzes your age, location, existing product usage, skin types and concerns through a proprietary, high-tech algorithm to build your own skincare routine. Designed for all genders and ethnicities, you wont end up with a drawer full of samples youll never touch, or worse, a product that irritates your skin. Kura only curates nontoxic, cruelty-free, nutrient-dense, effective indie brands for healthy, glowing skin.Individual products starting at $28

lilah b.:

Moisturize, balance and prime with lilah b.s Aglow Priming Oil

lilah b. -A three-in-one serum, moisturizer, and primer that can be worn alone or under makeup creating a smooth, flawless canvas for long-wear makeup application. Aglow Priming Oil is a fast-absorbing, silicone-free priming face oil that nourishes and hydrates skin. Formulated with a nutrient-rich trio of tamanu, jojoba and sweet almond oils to soften, smooth and comfort the skin. Infused with grape seed extract to help improve skin firmness and reduce fine lines and wrinkles. Enriched with purple tea extract to improve skin texture and tone for a natural radiant complexion. The perfect dose of nourishment to prep skin with an effortless glowing finish. $68

ADVERTISEMENT

Luzern:

Hydrate, soothe and boost luminosity with Luzerns new Alpine Rose Glacial Serum Masque.

Luzern-Infused with precious Ruby Powder, stem cells from the treasured Alpine Rose, a proprietary peptide-ferment, and an abundance of moisture factors and nutrients, this unconventional nectar mask provides instant hydration and calm, leaving skin velvety soft, smooth, and luminous. $150

Madeca Derma:

Madeca Derma Revitalizing Overnight Sleeping Mask

ADVERTISEMENT

Madeca Derma-This supercharged night mask powered by propolis that helps skin recover overnight for a more youthful look by morning. $27.99

MAKE:

Gently yet effectively cleanses to remove impurities while hydrating and balancing

MAKE Succulent Skin Gream-This serum weight facial cleanser, is a pH-balanced, sulfate-free universal gel that gently cleanses skin, effectively removing dirt, oil and impurities without stripping the skin of essential moisture. Supercharged with amino acid enriched surfactants that preserve the skin barrier. Also formulated with prickly pear, cactus, agave, niacinamide and sodium hyaluronate to provide nutrients. $24

ADVERTISEMENT

Manna Kadar Cosmetics:

Light up your skin with an all over radiance with Sheer Glow

Manna Kadar Cosmetics-Manna Kadar Cosmetics shimmer lotion works with all skin tones. Mix with foundation, BB cream, or body lotion to create a dewy glow for that radiant and youthful look. Get that extra highlighter look applying to cheek bones and collar bones for a more pronounced look. $29

Miami Beach Bum:

Formulated with oregano, aloe and jojoba to give your skin a full reset.

ADVERTISEMENT

Miami Beach Bum To our marine scientist founder, self-care means being active and around water. After constantly being in wet bathing suits she developed folliculitis on her bum and was unable to find a natural solution for it. Using her chemistry background, Ayssa crafted our signature Bum + Body Cream with the mission of bringing skin health to the forefront of self-care. Now with a full collection, each product has become an essential part of Ayssas personal ritual and we hope they can become a part of everyone's unique self-care ritual as well. $45

natureofthings:

natureofthings Clarifying Facial Polish combines the purifying action of a cleanser with the ... [+] resurfacing and glow-enhancing benefits of an exfoliant.

natureofthingsClarifying Facial Polish combines the purifying action of a cleanser with the resurfacing and glow-enhancing benefits of an exfoliant. A few drops of water activate the powder into a paste (for a milder formulation, simply add more water). Nutrient-rich lava ash from the Korean island of Jeju and Kisameet Glacial Clay penetrate deep into the skin to draw out impurities and oil, unclog pores and promote overall tightness and tone. Salicylic acid, lactic acid and papaya enzyme work gently to slough off dead skin cells responsible for dull complexions and uneven texture. Colloidal oatmeal and olive oil powder soothe and moisturize. Skin looks smooth, refreshed, and primed to absorb any subsequent products. $65

ADVERTISEMENT

No, Thank You:

An Oil For All Day

No, Thank YouFor whatever face you have to show the world today, our moisturizing oil replenishes your skin, repairing damage from UV and boosting your natural glow. Use it as often as you like, as a little extra help to welcome all the different emotions and expressions you need to communicate every day. Our vitamin C perfectly encapsulates our approach to skincare, specifically our commitment to making sure every ingredient really earns its place in the bottle formula over fads if you will. Vitamin C is an amazing ingredient but that doesnt mean you can just add it to a product and call it a day. You have to think about quality, concentration and combination. We use a shelf-stable form of vitamin C, in the right amount (sometimes more isnt more), combined with CBD and other ingredients that enhance its effectiveness. Its a holistic approach to skincare formulation that has become the hallmark of NTY products. $85

Nourishe:

Nourishe Glowing Skin Serum

ADVERTISEMENT

Nourishe-This waterless, gentle facial oil to help balance breakout-prone and sensitive skin. The rich blend of 32 botanicals gives you a smooth, energized complexion, boosting skin's collagen production and elasticity at the same time. The product comes in biophotonic glass, with minimal plastic packaging to maintain potency. $24.50

Obagi Clinical:

Exfoliate, smooth and retexturize skin with the Obagi Clinical Blue Brilliance Triple Acid Peel

Obagi Clinical-This is a one-of-a-kind facial peel that combines three potent acids to exfoliate, smooth and retexturize the skin for a more radiant-looking complexion. This powerful, award-winning at-home peel utilizes the strength of salicylic, glycolic and lactic acids to help minimize the appearance of uneven skin, reveal a brighter-looking, more youthful look, and keep pores clean. The self-neutralizing at-home peel is a 2-month series and comes with four 8mL vials - one to be used every two weeks - for a gradual peel with no downtime. $145

ADVERTISEMENT

Obakki:

This gift set is the ultimate recipe for silky, moisturized skindeeply nourishes, restores, ... [+] soothes and helps lock in moisture. A definite favourite for all skin types.

ObakkiObakki is a purpose-led lifestyle brand that connects people through handcrafted products and artisan ware. The Moisturizing Gift Set in Earthy Scent features a deeply moisturizing trio set of Nilotica Shea Butter, Whipped Shea Lotion and the Obakki Organic Sugar Scrub. The Earthy Scent is an invigorating blend of cedar, ho wood, and grapefruit, and is a definite favourite for all skin types. All Obakki skincare products feature 100% all-natural ingredients and never contain palm oils, artificial fragrance or colourants, parabens, sulfates, or animal products. $76 USD

One Ocean Beauty:

To use, close eyes and spray hydrating mist all over the face 3 times a day

ADVERTISEMENT

See the original post here:
Here's How To Get The Perfect Summer Skin Glow In 2021 - Forbes

Recommendation and review posted by Bethany Smith

Keila Torres knew during a conference trip to Florida she was going to meet the woman who saved her life. What she didn't expect was to see someone so familiar.

Torres, 44,of Worcester, Massachusetts,desperately needed a bone marrow transplant in 2016, when she was 39, to beatacute myeloid leukemia, a cancerthat starts in the bone marrow but often moves into the blood.

A bone marrow transplant isa treatment option for people withblood cancers, such as leukemia, and it replacesunhealthy blood-forming cells with healthy ones from a donor, according to Be The Match, a nonprofit that pairs peoplewith a donor.

She had slightly less than a 50% chance, according to Be The Match. But she beat thoseodds, thanks to Palm Desert resident Odalis Trinidad.

When the two women met on June 23, Torreshad a realization. Her body had been changing since the transplant, and now it started to make sense.

"My blood type changed to Odalis blood type.I developed allergies after the transplant, and she has allergies," Torres said. "Her hair is long, beautiful and really curly, and when my hair started to grow back, it was very curly, very tight curls. When I saw her, I was like, 'Wow, that's why my hair is like that.'"

"You basically become your donor. She lives in me," she added.

Dr. Ayad Hamdan, a bone marrow transplant specialist and board certified hematologist with the Eisenhower Lucy Curci Cancer Center, explained that since new stem cells from adonor replace the stem cells in a patients bone marrow, which is the "factory of our blood cells," the patient will have the same blood type as the donor.

He added it is possible for patients to develop allergies, and"most patients who receive chemotherapy or a transplant have the experience that their hair may grow back with a different texture," but the hair follicles themselves don't change.

Not only do the two women share hair textures and occasionally stuffy noses, they're driven by their desire to inspire others to help those in need.

Most 19-year-oldsare focused on having good times with their friends, not necessarily providing life-saving donations.

Trinidadsaid she tried to donate blood as often as she could, even though the process was always a bit uncomfortable either her arm would stop pumping enough blood, or her arm would be too sensitive. During one of her visits, she noticed a poster for Be The Match and decided to do some more research.

The process to join the donor registryseemed "really easy" for Trinidad, now 24.She received a registration kit to give a swab of cheek cells and sent it back in October 2015. Then camethe waiting period.

"If you get called, you get called; if you don't, well, at least you tried, right?" the Palm Desert resident said.

People between the ages of 18 and 44 can join the Be The Match donor registry. Cells from younger donors have the best chance of successful donations, according to the Mayo Clinic.

Due to a lack of diversity on the donor registry, white patients have a better chance of finding a match on the registry than do people of other races. According to the site, African Americans have a 29% chance, Asians and Pacific Islanders 47%, Latinos 48%, Native Americans 60% and whites 79%.

In July 2015, Torres, 38 at the time, learned she was diagnosed with Stage 3 breast cancer. With two young sons, ages 15 months and 5 years old at the time, she knew she had to fight to be there for her boys. After chemotherapy, radiation, lymph node removal and a bilateral mastectomy, she was declared cancer-free a year later.

The good news, unfortunately, was spoiled in September 2016.

"I felt like I was fine. I was recovering, I was spending time with my kids, I was going to work, my hair was growing back and I felt great," Torres said. While undergoing a bone marrow biopsy, she was told "there was something wrong" with routine lab work.She remembered asking her oncologist, "What's the worst that could happen?"

"If we find leukemia," Torres recalled her oncologist saying. "When I heard leukemia, I was like, 'Oh,that's not going to be me, it's probably something else.'"

But the biopsy showed she hadacute myeloid leukemia. It isa common type of leukemia in adults, although it accounts for just 1% of all cancers,according to Cancer.org.It is also generally uncommon to find in people younger than 45. Torres was 39.

"I was in shock. I was devastated. I had already gone through so many things," Torres said, "but in the back of my head I was thinking, 'I've been through breast cancer, I can do this.'"

But the gravity of the situation didn't hit her until she met the leukemia team at Massachusetts General Hospital. Walking into one of the clinic rooms, she remembers feeling "very claustrophobic,"like she was "running out of breath."

Torres began chemotherapy atMassachusetts General, but to have a betterchance at beating leukemia, she would need a bone marrow transplant.

The two women had plenty in common even before the transplant,Torres said, almost as if Trinidad was always her"missing puzzle piece." They both have birthdays in October, mothers from Guatemala (Torres grew up there as well) and they're both mothers.

The best match for a bone marrow transplant is when a patient and donor'shuman leukocyte antigen closely match. HLA"is a marker on our stem cells thatdetermines how our immune system responds," explained Hamdan. Those markers are used by an individual's immune system to know which cells belong in the body and which ones don't, according to Be The Match.

Doctors first looked to Torres' brother to see if he was a match. Siblings have a one in four chance of being a match since half of an individual's HLA markers are inheritedfrom their mother and the other halffrom their father, according to Be The Match. About seven out of 10 people won't have a close match with a family member, as was thecase with Torres. That's when people look to thedonor registry.

After Trinidad completed her cheek swab in October 2015, she essentially forgot about it since she didn't hear back from the registry. She received a phone call a year later.

"'Hey, I don't know if you remember you signed up for this, but this is what we do and we're calling to let you know that you have a possibility of saving someone's life,'" Trinidad recalled hearing.The only information she was given was the person needing the donationwas a female, 40 years old (Torres turned 40 in October 2016) and the type of leukemia. Nothing more, not even a name.

So, yes or no? It wastime to decide.

"I called them (the next day to learn) what did I need to do, what did they need from meto make sure it could be successful," she said.

Trinidad had blood work and other tests done prior to donation day. Her family was very supportive of her decision to help save a life, she said, whileit was a bit "hard for my friends to be on board."

"We were all 19, so they were like, 'You're crazy, you don't even know them and you're going to have this whole surgery for them?'I was like, "Well, yeah, I can save someone's life,'" Trinidad recalled. "You would want someone to do it for you, so how could you not do it?"

On donation day, donorsare put undergeneral anesthesia and marrow cells are taken from the back of the pelvicbone.

"The donor lies face down, and a large needle is put through the skin and into the back of the hip bone. Its pushed through the bone to the center and the thick, liquid marrow is pulled out through the needle," according to Cancer.org.Around 10%, or 2 pints, of marrow are collected, and the procedure takes up to two hours. The donor's body replaces those cells within four to six weeks.

Trinidad described the day in December 2016 as "nerve-racking,"but not because of the giant needle.

"I know everything that they're doing to me, but I can't, I literally cannot, know her perspective, what she is going through, how it is going to get to her," she said. "During this whole procedure, I'm nervous, I'm thinking, 'I hope it works, I hope it works.'I'm a match, but her body might not (accept the cells)well. I want to be sure that I'm doing the best I can so that it's the best for her."

To begin the transplant process, a receiving patient must undergo a conditioning regimen, which includes chemotherapy and sometimes radiation, to "wipe out" their immune system and leukemia cells, according to Hamdan.On transplant day, also called Day Zero, patients receive the donated cells through a blood transfusion.From Day Zero onward, the donated cells grow and make new blood cells, which is called engraftment, according to Be The Match.

Torres, admitted to the hospital on Thanksgiving, had a week straight of chemotherapy. Day Zero, which she considers one of her birthdays and her "rebirth," was Dec. 2, 2016.

It's normal for patients to feel weak, and Torres remembers being "sick to my stomach" the first few days after the transfusion. But her red and white blood counts started growing, she said, and slowly started feeling better. She was released from the hospital on Dec. 23, just in time for the holidays.

Both women had played a big part in each other's lives, and yet they still didn't know anything about one another.

Transplant recipients and donors have to wait one year before they can have direct contact with each other in the United States, according to Be The Match.

"This could only work if both of us want to know," Trinidad said."It was hard because I wanted to know her recovery, I wanted to know if it worked. What if it didn't work and they just didn't tell me anything at all?"

By the time the one-year mark came, the two women were ready to know something, anything,about each other.

It was an instant connection, almost as if they had known each other their entire lives, they both said. Finallyconnected on Facebook, they could get a glimpse of the other's family and see what they were up to. They talked and texted whenever they could.

It wasn't until a few weeks after their initial contact that Torres revealed to Trinidad that doctorsfound leukemia once again in January 2018.Torres would have to go through the transplant process all over again, but this time witha different donor.

Hamdan explained: "Transplants are most of the time the only chance for patients to be cured, and although there is a good chance of success, the cancer can come back. (It) depends on the disease, the age of the patient, the type of transplant."

Torres still wouldn't change a thing.

"She gave me life the first time around. I was able to come home and be with my kids for a year," Torres said. "Even if I had relapsed or not, Im so grateful for her for doing an act of kindness. At 20,Iwasnt thinking about stuff like that."

Trinidad, now a mother herself to3-month-old son Jimmy,said having her own child put thedonation into a whole new perspective.

"I really just am happy to give her that time with her kids. I now know how important and valued that time is," she said.

But thatwasn't the end of the journey.

They both had meeting each other in-person on their bucket lists, and when an opportunity came at aHOSA Future Health Professionals convention last month in Orlando, Floridaboth said "it was meant to be."

Representatives from Be The Match reached out to the two women and asked if they'd want to share their story to the students attending the conference. Trinidad was also a member of HOSA when she attended Palm Springs High School.

After years of texting, calling and social media lurking, they hugged on stage at the conference for quite a long time, admitted Trinidad, and "neither of us wanted to let go." She describedthe moment as "surreal,"finally seeing "the life that I gave her."

And for Torres, to see the woman who went froman anonymous lifesaver to a dear friend and a bit of a look-alike,saying thank you in-personis a moment she'll never forget.

"Theres no way that Iwill ever be able to repay her because theres no price with what she did," Torres said. "Im think I'm still kind of digesting all the emotions that came with it, but the one thing I know isIm full of gratitude for what she did for me.

Trinidad hopes more people will join the donor registry "it's so easy," she reiterated and be there to answer the call if they end up being someone's best match.

"I'm a donor because I wanted to be one," Trinidad said. "I know it required me physically giving up some bone marrow, but itsaved someones life, and I would do it again."

Torres, too, can attest to that: "If it hadnt been for her the first time around, honestly I dont think Iwould be here."

HOW TO JOIN THE BE THE MATCH REGISTRY

Visithttps://bethematch.org/to learnhow to join the registry, request a cheek swab and what the next steps are if you're a match.

Ema Sasic covers health in the Coachella Valley. Reach her at ema.sasic@desertsun.com or on Twitter @ema_sasic.

Go here to see the original:
Palm Desert resident meets the woman whose life she saved with bone marrow transplant - Desert Sun

Recommendation and review posted by Bethany Smith

Stem cells are basically cells with the capacity to turn into different kinds of cells. These cells are used in the manufacture of blood, skin, heart, lungs, pancreas and a variety of other organs. They play an important role in organ transplants, tissue engineering and in the therapy of Parkinsons disease.

Request Here PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/4222

In fact, stem cells harvested from the adult marrow have already helped treat some of these diseases. Scientists have succeeded in transplanting adult stem cells from the anogenital area of the male reproductive organ to patients with chronic diseases like Parkinsons disease, a disease that affects both the nervous and the cardiac systems. This procedure has proven to be very effective in treating the disease since it stimulates the production of the living cells in the diseased area. Since adult stem cells could help treat Parkinsons disease, the researchers tested their idea in animals and succeeded. Stem cells from the adult bone marrow have also shown great potential in treating diseases like arthritis, psoriasis and multiple sclerosis.

Market Dynamics

High prevalence of chronic disorders is expected to propel growth of the global stem cells market. For instance, according to the study, Prevalence of Parkinsons disease (PD) across North America, published in July 2018 in the journal Nature, the number of people suffering from PD is expected to reach 930,000 in 2020 and 1,238,000 in 2030.

R&D in stem cells is expected to offer lucrative growth opportunities for players in the global stem cells market. For instance, in December 2020, researchers from the Wake Forest Institute for Regenerative Medicine demonstrated that stem cells found in amniotic fluid meet an essential test increasing their likelihood of becoming specialized cell types.

Competitive Analysis

Major players operating in the global stem cells market include, Advanced Cell Technology, Inc., Angel Biotechnology Holdings PLC, Bioheart Inc., Lineage Cell Therapeutics., BrainStorm Cell Therapeutics, Inc., California Stem Cell Inc., Global Stem Cells Group, Celgene Corporation, Takara Bio Europe AB, Cellular Engineering Technologies, Cytori Therapeutics Inc., Osiris Therapeutics, and STEMCELL Technologies Inc.

Major players operating in the global stem cells market are focused on adopting M&A strategies to enhance their market share. For instance, in October 2020, Global Stem Cells Group signed an agreement with Bioscience Cell Factory, a Dubai-based healthcare company, which will allow GSCG to act as their representatives operating in both the Middle East and Latin America.

Some of the Major Highlights of TOC covers:

Regional Market Analysis

Segment Market Analysis (by Type)

Segment Market Analysis (by Application)

Major Manufacturers Analysis

Purchase this Report at https://www.coherentmarketinsights.com/promo/buynow/4222

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. ShahCoherent Market Insights1001 4th Ave, #3200Seattle, WA 98154Phone: US +12067016702 / UK +4402081334027Email: sales@coherentmarketinsights.com

The rest is here:
Stem Cells Market 2021: Rising with Immense Development Trends across the Globe by 2027 The Manomet Current - The Manomet Current

Recommendation and review posted by Bethany Smith